Possible links between Crohn’s disease and Paratuberculosis

Report of the
Scientific Committee on Animal Health and Animal Welfare
Adopted 21 March 2000
Possible links between Crohn’s disease and Paratuberculosis.

Contents

1. REQUEST FOR AN OPINION ........................................................................................................ 4
   1.1. BACKGROUND ..................................................................................................................... 4

2. M. AVIUM. SUBSP. PARATUBERCULOSIS AND RELATED STRAINS ..................................... 6
   2.1 DESCRIPTION OF M. AVIUM ........................................................................................... 6
   2.2 DESCRIPTION OF M. AVIUM SUBSP. PARATUBERCULOSIS ............................................ 6
   2.3 DIVERSITY OF M. AVIUM SUBSP. PARATUBERCULOSIS AND STRAIN DIFFERENTIATION ... 7

3. DESCRIPTION OF PARATUBERCULOSIS ........................................................................ 9
   3.1 HISTORY ........................................................................................................................... 9
   3.2 AETIOLOGY ....................................................................................................................... 9
   3.3 PATHOGENESIS ................................................................................................................ 10
      3.3.1 Genetic Susceptibility .............................................................................................. 10
      3.3.2 Immunopathology .................................................................................................... 10
   3.4 PATHOLOGY .................................................................................................................... 12
   3.5 CLINICAL FEATURES ....................................................................................................... 13

4. DESCRIPTION OF CROHN’S DISEASE ............................................................................. 14
   4.1 HISTORY .......................................................................................................................... 14
   4.2 AETIOLOGY .................................................................................................................... 14
   4.3 PATHOGENESIS .............................................................................................................. 15
      4.3.1 Disease mechanisms ................................................................................................ 15
      4.3.2 Genetic susceptibility ............................................................................................. 15
      4.3.3 Immunopathology .................................................................................................. 16
   4.4 PATHOLOGY .................................................................................................................... 17
   4.5 CLINICAL FEATURES ....................................................................................................... 18

5. EPIDEMIOLOGY AND GEOGRAPHICAL DISTRIBUTION OF BOTH DISEASES ... 22
   5.1 EPIDEMIOLOGY AND GEOGRAPHICAL DISTRIBUTION OF PARATUBERCULOSIS IN ANIMALS ... 22
   5.2. EPIDEMIOLOGY AND GEOGRAPHICAL DISTRIBUTION OF CROHN’S DISEASE .............. 23
   5.3 IS THE INCIDENCE OF BOTH DISEASES CHANGING? ....................................................... 26
   5.4 IS THERE A CAUSAL ASSOCIATION BETWEEN THE GEOGRAPHICAL INCIDENCE/PREVALENCE OF CROHN’S DISEASE AND THAT OF PARATUBERCULOSIS? ........................................... 26

6. DIAGNOSIS AND CONTROL OF PARATUBERCULOSIS ............................................. 28
   6.1 INTRODUCTION ................................................................................................................. 28
   6.2 DETECTION OF THE CAUSATIVE AGENT ....................................................................... 29
      6.2.1 Microscopical examination ....................................................................................... 29
      6.2.2 Cultural methods....................................................................................................... 29
      6.2.3 Polymerase Chain Reaction (P.C.R.) ...................................................................... 30
   6.3 DETECTION OF AN IMMUNE RESPONSE TO M. AVIUM SUBSP. PARATUBERCULOSIS ....... 31
      6.3.1 The complement fixation test .................................................................................. 31
      6.3.2 The absorbed ELISA ............................................................................................... 32
      6.3.3 Agar-gel-immuno-diffusion test (AGID) .................................................................. 32
      6.3.4 Cellular Immunity Tests .......................................................................................... 33
   6.4 TREATMENT OF PARATUBERCULOSIS IN ANIMALS ...................................................... 33
   6.5 VACCINATION AGAINST PARATUBERCULOSIS ............................................................... 34
   6.6 CONTROL AND ERADICATION PROGRAMMES ................................................................. 36
7. M. AVIUM SSP PARATUBERCULOSIS INFECTION IN HUMANS. ............................... 39

7.1 DETECTION OF MAP IN CROHN’S DISEASE BY CULTURE AND PCR. .................................................. 39
7.2 IMMUNOLOGICAL RESPONSES TO MAP IN HUMANS WITH CROHN’S DISEASE. ............................... 43
7.3 TREATMENT OF CROHN’S DISEASE WITH ANTIMYCOBACTERIAL DRUGS. ...................................... 46

8. EXPOSURE OF HUMAN POPULATIONS TO M. AVIUM SSP. PARATUBERCULOSIS 49

8.1 NON-DIETARY EXPOSURE ..................................................................................................... 49
8.2 DIETARY EXPOSURE ............................................................................................................. 49
  8.2.1 Raw milk ................................................................................................................... 49
  8.2.2 Heat treated milk ....................................................................................................... 50
  8.2.3 Other foods ............................................................................................................... 51
  8.2.4 Water supplies .......................................................................................................... 51

9. SUMMARY ........................................................................................................................................ 52

10. RESEARCH ..................................................................................................................................... 54

10.1 CROHN’S DISEASE .................................................................................................................. 54
10.2 PARATUBERCULOSIS .............................................................................................................. 54

11. CONCLUSIONS ......................................................................................................................... 56

12. REFERENCES ............................................................................................................................ 57

13. ACKNOWLEDGEMENTS ......................................................................................................... 74
1. Request for an opinion

In the light of speculation that Crohn’s disease in man and paratuberculosis in animals (also known as Johnes disease) is caused by the same organism *Mycobacterium avium* subsp. *paratuberculosis*, the Scientific Committee on Animal Health and Animal Welfare is asked to examine and comment on the evidence for and against a causative link between the two diseases.

1.1. Background

Paratuberculosis is a chronic inflammation of the intestine in animals caused by a slow growing and difficult to culture bacterium called *Mycobacterium avium* subsp. *paratuberculosis* (*Map*). Paratuberculosis can affect many different animals including primates. It is particularly prevalent and apparently increasing in European dairy herds and other domestic livestock such as sheep, goats and farmed deer\(^1,2\).

Paratuberculosis is a serious disease with considerable economic consequences. The net cost to farmers of subclinical infection with *Map* in their animals, was estimated in Europe in 1987 to be £209 per infected dairy cow mostly due to reduced milk production.\(^3\) Recent work in the US\(^4\) has estimated that paratuberculosis costs dairy farmers there around $100 per cow in moderately infected herds rising to over $200 per cow in heavily infected herds. These losses were mainly due to decreased milk production and increased cow replacement costs. The study estimated the costs in terms of reduced productivity alone to be $200 to $250 million per annum which would be a considerable underestimate of the total costs due to this disease. In Spain, losses in sheep have been estimated to be €120 and €60 for clinical cases in dairy and meat sheep respectively\(^5\).

Besides losses due to emaciation and death, infected animals show decreased productivity, increased infertility and susceptibility to other infections\(^6\). Other causes of culling like mastitis or infertility were significantly higher in cows infected with *Map* than in non-infected animals. In milk production, a decrease of 16% was observed between the current lactation and the lactation two seasons previously in clinically affected dairy cows\(^3\). As in other diseases, poor health leads to poor welfare.

Crohn’s disease is a chronic inflammation of the intestine in humans. A major multi-centre European study\(^7\) has calculated an incidence rate for Crohn’s disease of 5.6 per 100,000 per year, though there were considerable local differences. The disease is lifelong, though considerable periods of remission may occur. It is estimated that over 200,000 people are affected by this disease in the European Union.

Data of the cost of Crohn’s disease to society in Europe are not available. However, a Swedish study\(^8\) has shown that in 1994 Sweden spent over €40 million on patients with this condition, 29% of which were direct costs i.e. costs for in-patient care, ambulatory care and drugs. Indirect costs i.e. sickness leave and early retirement constituted 71% .
Crohn's disease results in substantial morbidity and high use of health services. Mortality is not usually a feature of the disease though patients, particularly the young, have double the risk of dying compared with a matched group drawn from the general population, mainly because of complications associated with the disease. A US study found that for a representative patient, projected lifetime costs were $125,404 using mean charges. Overall, the total annual medical costs in the US were estimated in 1992 at $1 billion-$1.2 billion. These costs were unevenly distributed with the top 2% of patients accounting for around 29% of the costs. If disability payments and the cost of early retirement are taken into account the total cost of this disease is much higher.

This report has confined itself to an examination of the possibility that Crohn’s disease is caused by Map. It does not examine other possible causes of Crohn’s disease in detail. The examination has focussed on a number of aspects, a description of the organism, a comparison of both diseases, a discussion of the geographical prevalences of both diseases, diagnosis and control of paratuberculosis in animals, detection of the organism in Crohn’s patients, immunological responses to the organism in Crohn’s patients, a discussion on the effects of various treatments and finally a consideration of the possibility of humans being exposed to the organism from animal sources.
2. \textit{M. avium. subsp. paratuberculosis} and related strains

2.1 Description of \textit{M. avium}

\textit{Mycobacterium avium} subsp. \textit{paratuberculosis} belongs to the Family \textit{Mycobacteriacea}, Chester, 1897. The main attributes of these bacteria is their slow growth rate and resistance to treatments with acid and alcoholic compounds. This is due to their strong cellular wall, with a high lipid composition. \textit{Mycobacterium avium} form a large group of closely related mycobacteria which can be subclassified into \textit{Mycobacterium avium} subspecies \textit{avium} (\textit{Maa}), \textit{Mycobacterium avium} subspecies \textit{silvaticum} (\textit{Mas}), and \textit{Mycobacterium avium} subspecies \textit{paratuberculosis} (\textit{Map})\textsuperscript{12}. \textit{Mas} (originally called the woodpigeon strain) contains the specific insertion sequences IS\textsubscript{901} and IS\textsubscript{902}\textsuperscript{13,14} and has been also reported to produce a disease resembling paratuberculosis in calves and deer\textsuperscript{15,16,17,18}. \textit{Maa} are becoming better defined by molecular methods including rDNA sequencing and restriction fragment length polymorphism (RFLP) genotyping exploiting the increasing number of insertion elements (IS) identified in this group of organisms. \textit{Maa} are very widely distributed in the natural environment including soil and apparently healthy animals, birds and humans. The insertion elements they contain include IS\textsubscript{1245}\textsuperscript{19}, IS\textsubscript{110}\textsuperscript{20}, IS\textsubscript{1311}\textsuperscript{21} and IS\textsubscript{1626}\textsuperscript{22}. These have been used to type \textit{Maa} causing infections in animals and humans\textsuperscript{23,24}. \textit{Maa} are generally opportunist pathogens and only cause infection and disease in debilitated hosts.

In culture, colonies of \textit{Maa} may be smooth or rough and the switch in colony type may occur in repeated sub-cultures following the first isolation from the sample. Smooth to rough transition in \textit{Maa} serovar 2 is associated with specific genetic deletions and irreversible loss of pathogenicity\textsuperscript{25}. Growth in culture is usually visible after more than ten days at 37°C, which is the optimal temperature, and may require mycobactin and/or special media other than egg based media. Growth may be stimulated by pH 5.5 or pyruvate. Strains do not produce niacin, peroxidase, nitrate reductase, urease, arylsulfatase, penicillinase, or beta-glucosidase and do not hydrolise Tween 80 in 10 days. Strains produce small amounts of thermoresistant catalase. All strains have the same mycolic acid pattern and are resistant to thiophene-2-carboxylic acid hydrazide and isoniazid. Strains may be susceptible to p-nitrobenzoate, ethambutol, pyrazinamide, rifampin, and streptomycin. Most strains are susceptible to ansamycin. The reference strain is strain ATCC 25291. The species includes both potential and obligate pathogens and is divided into subspecies on the basis of pathogenicity and host range\textsuperscript{12}.

2.2 Description of \textit{M. avium} subsp. \textit{paratuberculosis}

\textit{M. avium} subsp. \textit{paratuberculosis} possesses the properties of \textit{M. avium} along with some additional features. The organism causes paratuberculosis, a chronic enteric disease in animals. The reference strain is strain ATCC 19698\textsuperscript{12}.
The main distinguishing feature of *Map* is its slow growth and the dependency on exogenous mycobactin for in vitro growth. Mycobactin is an iron-chelating agent produced by all other mycobacteria. However, *Map* does not produce, or produces an insufficient amount of mycobactin. It is closely related to other *M. avium* bacteria, sharing some antigenic determinants. Different strains of this bacterium have been reported: a bovine strain, a pigmented strain and strains isolated from small ruminants that seem to grow slower than bovine ones. Strains obtained from sheep and goats seem to be more difficult to culture. A specific insertion sequence of *Map*, IS900, has also been reported.

### 2.3 Diversity of *M. avium* subsp paratuberculosis and strain differentiation

The development of reliable techniques that can be used to examine diversity in the *M. avium* complex has evolved over a number of years and encompasses a range of techniques directed at phenotypic and genetic characteristics. For example, numerical taxonomy that analyses a panel of phenotypic properties can distinguish three subspecies of *M. avium*, viz. *M. a. avium*, *M. a. subsp. silvaticum* and *M. a. subsp. paratuberculosis*. However, this is a complex approach and a more common way of differentiating closely related species is to exploit differences in the composition of their genomes. Molecular techniques targeting rRNA genes have been used extensively for establishing taxonomic and evolutionary relationships between closely related organisms. Unfortunately, each of the rRNA genes (16S, 23S and 5S) as well as their intergenic spacer regions are highly conserved within the *M. avium* complex. Analysis of these regions has demonstrated the high genetic homology of these organisms and failed to discriminate *M. avium* and *Map*. Fortunately, identification of a specific insertion element, IS900, in *Map* has greatly simplified the detection of this organism and its differentiation from *M. avium*. Most research on diversity and strain differentiation within the *M. avium* complex has focused on molecular techniques to detect RFLPs, which have been exploited successfully to reveal genetic diversity in many organisms. Conventional restriction endonuclease analysis and field inversion gel electrophoresis can discriminate *Map* from other *M. avium* species, but are unable to differentiate different strains of *Map*. RFLP analysis can be improved by hybridising the DNA fragments with specific probes. Such analysis of *M. avium* isolates, using IS1245 and IS1311, has revealed a high degree of diversity among human and porcine strains. Similar analyses of *Map* have employed both IS900 and IS1311. Using the IS900 insertion sequence as a hybridisation probe, around 20 different RFLP types have been identified, reflecting some differences between strains. In general, the observed polymorphisms have not been associated with the animal of origin. However, this insertion element has specific integration targets, which place constraints on the possible number of polymorphisms. RFLP analysis using IS1311 as a probe detects fewer polymorphisms than IS900, which probably reflects the lower copy number of IS1311 elements. Whether the IS1311 polymorphisms overlap the IS900 polymorphisms and provide additional epidemiological information has not been
assessed. Interestingly, point mutations in IS1311 have allowed differentiation of isolates originating from sheep and cattle in Australia\textsuperscript{45,46}. Unless new repeated DNA sequences that are specific for Map can be identified, the use of RFLP analysis in epidemiological studies of Map will be limited.

Pulsed field gel electrophoresis (PFGE) is useful for strain differentiation of human isolates of \emph{M. avium}, particularly those from AIDS patients\textsuperscript{47,48,49,50}. This technique has not been applied extensively to strains of Map and more work is needed to determine its potential\textsuperscript{51,52,53}.

Although IS900 has 14-16 specific integration sites, six appear to be variably inserted or rearranged, allowing the discrimination of eight genotypes. This feature has permitted the development of a multiplex PCR to identify which integration sites are present in any genome and has been able to discriminate isolates from different host species e.g., cattle, sheep and man\textsuperscript{54}. This technique, therefore, warrants fuller assessment and may be a useful tool in epidemiological investigations. There is a great need to develop non-targeted techniques, which may reveal greater diversity. Randomly amplified polymorphic DNA (RAPD) patterns produced by PCR have been shown to be highly discriminatory for many bacteria and have been used successfully to type clinical isolates of \emph{M. tuberculosis} and \emph{M. avium}\textsuperscript{55,56,57}. Analyses of Map by this technique have produced conflicting results, although some diversity between the isolates was reported\textsuperscript{58,59}.

In summary, the currently available evidence points to a high degree of genetic homogeneity within Map, and current characterisation techniques are not yet sufficiently developed to support detailed epidemiological studies by differentiating between mycobacterial strains.
3. Description of Paratuberculosis

3.1 History

Paratuberculosis was first described in Germany in 1895 by Johne and Frothingham\textsuperscript{60}. They demonstrated the presence of acid-fast bacilli in affected animals and thought that the disease was an atypical form of tuberculosis. Twort isolated the causative organism in 1910 and named it \textit{Mycobacterium enteriditis chronicae pseudotuberculosa bovis johne}. The disease later became known as paratuberculosis or Johne's disease and the causative agent \textit{Mycobacterium avium} subsp. \textit{paratuberculosis} (\textit{Map}). The name \textit{Mycobacterium johnei} has also been used in the past.

3.2 Aetiology

Paratuberculosis is a chronic digestive disorder of both wild and domestic ruminants. The disease is characterised by a granulomatous enteritis that provokes a progressive weight loss and ends with the death of affected animals. Paratuberculosis is a contagious and enzootic disease of ruminants caused by the multiplication of a specific bacterium, \textit{Map} in the mucous membrane of the intestine. The organism, which is described in detail in Chapter 2, can also infect a wide range of other domestic and wild (free-living or captive) species including primates. This mycobacterium has recently been isolated in wild rabbits suffering a chronic granulomatous enteropathy\textsuperscript{61} and also from their predators, i.e. foxes, weasels and stoats\textsuperscript{62}.

The infection can be transmitted by either direct or indirect contact of infected animals with susceptible animals. Transmission occurs mainly by the faecal-oral route. Bacilli are ingested most commonly in large numbers when young animals nurse on teats which have been contaminated by faeces of shedding animals\textsuperscript{63}. These faeces may contaminate pastures, feed and water. The ability of this mycobacterium to resist destruction in the natural environment (it can survive nine months or longer outside an animal) makes prevention and control of paratuberculosis more difficult\textsuperscript{64}.

\textit{Map} has also been recovered from the uterus and placenta of infected cows and intrauterine infection of the foetus sometimes occurs. However, classical lesions of paratuberculosis have not been recognised in infected foetuses. Although \textit{Map} has been isolated from the semen of infected bulls, venereal transmission by artificial insemination or natural service is unlikely\textsuperscript{1,65}. There appears to be an age-related resistance to the development of new paratuberculosis infections. Animals infected in the first few months of life are the most susceptible\textsuperscript{66,67}. Adult animals are quite resistant. Although infections are usually initiated during calfhood, clinical disease does not appear until adulthood. Whether or not the exposed calf becomes infected depends on the number of bacilli ingested and the defence mechanisms of the host\textsuperscript{68}. The infection persists in breeding stocks after the introduction of infected animals.
The long incubation period of the disease allows mycobacterial shedding in faeces by animals for up to 18 months before clinical signs become apparent, but shedding is particularly high (up to $5 \times 10^{12}$ mycobacteria per day) during clinical expression of the infection.

Risk factors include intensive farming systems, acid soils, low dietary intake, stress related to transport, lactation and parturition and immunosuppression by agents such as bovine virus diarrhoea virus (BVDV). Close contact of susceptible animals with contaminated faeces is an important influence and may, because of the different husbandry methods, account for the reports of a higher prevalence in dairy cattle than in beef cattle.

### 3.3 Pathogenesis

#### 3.3.1 Genetic Susceptibility

Some breeds of cattle are commonly regarded as being particularly susceptible to paratuberculosis (Jersey, Limousin) but this aspect has not been studied in detail.

#### 3.3.2 Immunopathology

Once ingested, the bacilli immediately penetrate the mucosal surfaces of the gastrointestinal tract and are phagocytised by macrophages. The portal of entry is the gut associated lymphoid tissue (Peyers patches), both in the ileum and in the jejunum. These patches reach their maximum development about the time of birth and progressively disappear afterwards, though patches in the jejunum and ileocaecal valve region can persist in adult animals. This could be one of the explanations for the highest susceptibility to the infection occurring in young animals. Once within the macrophages, the bacilli remain viable and protected from humoral factors. Generally, a granulomatous lesion first starts to develop in the jejunal and ileocaecal Peyers patches area. At this stage lesions can persist as latent for long periods of time. Later, as the infection progresses, lesions will affect different parts of the Peyers patches related mucosa and finally will spread to wide areas of the intestine, causing the typical granulomatous enteritis. In the normal course of the infection, a cell-mediated response is seen initially. Later, as the disease progresses, there is a humoral response initiated by the release of bacilli from dying macrophages.
The existence of a wide immunological and histopathological spectrum, dependant on the host response, which was proposed initially in the case of leprosy has subsequently been applied to different mycobacterioses such as paratuberculosis. At one end of this spectrum, the tuberculoid extreme is located where the host offers a strong cellular immune response with a very low humoral response. At the opposite extreme of the spectrum one finds the lepromatous forms associated with a weak cellular immune response but with a strong humoral response. Between both extremes one finds the so-called borderline forms (borderline-lymphocytic and borderline-lepromatous forms). Animals showing these borderline forms exhibit the most severe clinical signs.

When culled animals from an infected sheep flock are studied, a range of lesions may be found, which may be delimited or diffuse. The former are not usually considered in pathological studies since they are only observed in apparently healthy sheep. However they represent about two thirds of the total number of infected animals and can be further divided into focal-tuberculoid and multifocal tuberculoid types. Among clinically affected animals, different pathological pictures can be found with varying amounts of bacilli in the lesions, depending on the immune status of the host. Some can show the diffuse non-lymphocytic multibacillary forms (borderline-lepromatous), with high amounts of bacilli and a strong humoral response whereas others could present diffuse lymphocytic paucibacillary forms (borderline-tuberculoid), with few or no bacilli and a strong cell-mediated immune responses. In summary, animals from a paratuberculosis infected flock can present varying immunological and pathological pictures and be located in different positions in the spectrum. All of these different immunological responses may appear at any time and the disease presentation can change from the limited to diffuse forms during the course of the infection. An understanding of this feature is especially important because the response of the animals to diagnostic tests is associated with their location in the spectrum.
3.4 Pathology

The principal pathological changes centre on the intestine and the related lymphatic and lymphoid tissues although, in advanced cases, pathology associated with cachexia may be present. It must be emphasised that gross changes in sheep and goats with paratuberculosis are often lacking or difficult to detect, and may not resemble those of the disease in cattle.

In advanced cases there is wasting with gelatinous atrophy of fat depots and serous effusion into body cavities. In the intestine, macroscopic changes principally affect the terminal ileum, but may extend to involve the jejunum and colon. The ileum may be thickened and may feel doughy when handled, but more usually the only visible change in the lining is a slight fleshy or velvety thickening, or a faint granularity of the surface, perhaps with slight congestion. These subtle changes may be overlooked in a cursory examination. Occasionally, there may be a tendency for the mucosa to form fissures when bent over the fingers. Where infection with pigmented strains occurs, the mucosal lining takes on a pathognomonic bright yellow colour, due to the presence of pigmented Maps in the lamina propria.

The afferent lymphatic vessels in the intestinal peritoneum and mesentery may be thickened and convoluted, and contain numerous small (1-4mm) whitish nodules, which may be caseous or even calcified. Similar nodules or white flecks may be seen on the peritoneal surface of the ileum, or the cut surface of the intestinal wall or the mesenteric lymph nodes. The latter are almost invariably enlarged and prominent at necropsy.

Although all clinical cases present as an afebrile, chronic wasting, the severity of the signs is unrelated to the extent of the pathology. In cattle, sheep and goats, two distinct types of pathology are apparent, based on the abundance of mycobacteria and cellular infiltrate. The more common form, known as borderline-lepromatous or multibacillary, is characterised by numerous acid-fast Map packing the cytoplasm of the many large macrophages that infiltrate the mucosa in all cases, forming extensive, diffuse sheets. Lymphocytes and granulocytes are present in much lower numbers. Occasional multinucleate, Langhans-type giant cells may be seen. These changes cause marked thickening of the intestine.

The less common form, known as lymphocytic or paucibacillary, comprises approximately 30% of cases in sheep and goats. It is characterised by a more marked lymphocytic infiltrate with scattered, small focal granulomata and giant cells. Lesions may exhibit caseation, calcification or fibrosis, the resultant nodular lesions being visible macroscopically. This tendency for lesions in sheep to undergo caseation or calcification is an important point of differentiation from the lesions of Johne's disease in cattle. Acid-fast Map are sparse or undetectable in lymphocytic lesions, and are usually absent from caseous or calcified foci.

The two types of pathology in paratuberculosis correlate with different host responses to the bacterium. Sheep with multibacillary disease have a strong antibody response but a weak, or absent, cell-mediated immunity (CMI) as indicated by poor skin hypersensitivity and predominant Th2-like cytokines (IL-4 and IL-10). Electron microscopy indicates that Map appears to be able to multiply in epitheloid cells in these lesions. Animals with paucibacillary disease show a strong CMI response and strong skin hypersensitivity, poor or absent antibody response and predominant Th1-like cytokines (IL-2 and IFN-γ). In these lesions, the bacteria appear to degenerate in
epitheloid macrophages. Thus, this form of paratuberculosis appears to reflect the ability of the host to reduce the bacterial load in the intestine.

### 3.5 Clinical Features

It is important to recognise that paratuberculosis has a protracted incubation period and that clinical disease is the terminal stage of this process. The onset of clinical disease is unpredictable, but may be precipitated by parturition, lactation or by stressful events.

In all ruminants, clinical disease is characterised by a progressive, afebrile weight loss that leads to emaciation, brisket or submandibular oedema and poor coat quality (roughness, loss of pigmentation, alopecia, ‘wool-slip’), despite maintaining a good appetite. A drop in milk yield has been reported to occur in the lactation preceding that in which clinical disease became apparent. A major feature of the illness in cattle is chronic, intractable diarrhoea, although in some animals this may be intermittent. In contrast to cattle, diarrhoea is not a feature in small ruminants. This is probably due to their greater ability to reabsorb water in the large intestine, though in advanced cases the faeces may become soft and unformed.

Decreased serum concentrations of calcium, total protein and albumin have been reported in both cattle and sheep with clinical paratuberculosis.

Although the disease is always chronic, there is considerable variation in the course. In some instances, the disease progresses relatively rapidly with the interval between the appearance of wasting and death measured in months. In other cases, after the initial loss of condition, there may be no clinical deterioration for long periods.

Since the first signs of clinical disease are progressive weight loss and drop in milk production, most farmers will note this and may cull the animal without requesting further diagnosis. For this reason the actual number of clinical cases (and the prevalence) of paratuberculosis is greatly underestimated.
4. Description of Crohn’s Disease

Crohn’s disease is a non-specific chronic transmural inflammatory disease of humans that most commonly affects the distal ileum and colon but may also occur in any part of the gastrointestinal tract from the mouth to the anus and perianal area. It is a lifelong disease and has no cure. Quality of life is compromised\textsuperscript{84, 85} and patients afflicted with the disorder have to learn to live with the threat of significant morbidity throughout their lives. It generally affects persons during the prime of life, with highest incidence being in the age group 15-24, often from homes where early hygiene has been good\textsuperscript{86, 87}. The disease is characterised by intermittent episodes of relapse, remission and recurrence requiring one or more surgical intervention in a large proportion of patients\textsuperscript{88}. However, with the advent of new therapeutic agents such as aminosalicylates (5-ASA), budesonide and immunosuppressive drugs, medical management has become more common.

4.1 History

Crohn’s disease derives its name from the description of eight cases of regional ileitis described by Crohn, Ginsburg and Oppenheimer in 1932 at the Mount Sinai Hospital in New York\textsuperscript{89}. However, the first clear description of the disease was made by Dalziel in 1913 at the Western Infirmary in Glasgow\textsuperscript{90}. The earlier term of regional ileitis was replaced by regional enteritis in 1960 when it was recognised by Lockhart-Mummery and Morson that the disease was not confined to the ileum when they described primary Crohn’s disease of the colon\textsuperscript{91}. This entity was subsequently termed granulomatous colitis by American clinicians. Together with ulcerative colitis and unclassified chronic colitis, Crohn’s disease belongs to a spectrum of diseases more generally designated as “Chronic inflammatory bowel diseases”.

4.2 Aetiology

The aetiology of this disease is unknown. Immunological factors have been extensively examined, as have possible infectious agents. The list of bacteria examined is long and has been reviewed by Thompson\textsuperscript{92} (see table 1).

<table>
<thead>
<tr>
<th>Klebsiella spp.</th>
<th>Campylobacter jejuni</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia spp.</td>
<td>Campylobacter faecalis</td>
</tr>
<tr>
<td>Eubacterium spp</td>
<td>Listeria monocytogenes</td>
</tr>
<tr>
<td>Peptostreptococcus spp</td>
<td>Brucella abortus</td>
</tr>
<tr>
<td>Bacteroides fragilis</td>
<td>Yersinia pseudotuberculosis</td>
</tr>
<tr>
<td>Enterococcus faecalis</td>
<td>Yersinia enterocolitica</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>Mycobacteria spp.</td>
</tr>
</tbody>
</table>
Several viruses have also been investigated, the most prominent being the measles virus. However, publications from the Chief Medical Officer Department of Health in the UK and the World Health Organisation have indicated a consensus conclusion that measles viruses are not associated with Crohn’s disease.93,94.

With increasing concern about the transmission of infectious diseases from animal to man, attention has refocused on *Mycobacterium paratuberculosis* as a candidate organism in the aetiology of Crohn’s disease (see Chapter 7).

### 4.3 Pathogenesis

#### 4.3.1 Disease mechanisms

The pathogenesis of Crohn’s disease probably involves an interaction of genetic and environmental factors, but the precise mechanism responsible for initiating chronic intestinal inflammation remains unclear. Irrespective of the aetiologic agent, three theories of disease mechanisms in Crohn’s disease are currently under consideration: 1) reaction to a persistent intestinal infection, 2) existence of a defective mucosal barrier to luminal antigens, and 3) a dysregulated host immune response to ubiquitous antigens.95

Another attractive hypothesis which fits well with the currently recognised role of cytokin imbalance and with observations in experimental colitis, is the breakdown of tolerance against microbial flora of the gut.96 Cigarette smoking has also been linked to the long-term course of Crohn’s disease and as well as to the recurrence of the disease after surgery.97,98.

#### 4.3.2 Genetic susceptibility

Whether Crohn’s disease is primarily an inherited or acquired disorder has been explored in recent studies of familial aggregation in Belgium, France, the United States, and the United Kingdom. The investigators found greater than expected concordance for site and clinical type of Crohn’s disease within individual families as well as pattern of young age at disease onset and more complicated disease among familial cases as compared with sporadic cases. These studies were criticised for their statistical approach to risk estimates, but they provide strong evidence that genetic factors are important determinants of susceptibility and disease behaviour in Crohn’s disease. Concordance rates in siblings and in monozygotic twin pairs in Crohn’s disease suggest that the genetic contribution to disease pathogenesis is at least equivalent to that in other common immune-mediated diseases (multiple sclerosis, insulin-dependent diabetes mellitus). A simple Mendelian pattern of disease inheritance is not evident. The epidemiological data are most consistent with Crohn’s disease and ulcerative colitis being polygenic diseases, sharing some, but not all, susceptibility loci.104,105.
Systematic screening of the human genome for susceptibility loci is now practicable in polygenic disorders, and has been successfully applied in Crohn’s disease. Four independent studies\textsuperscript{106,107,108,109,110} have all demonstrated linkage between susceptibility to Crohn’s disease and a region on chromosome 16; in addition, two studies\textsuperscript{103,111} have also implicated an area on chromosome 12 as involved in the pathogenesis of both Crohn’s disease and ulcerative colitis.

These data promise real advances in the understanding of the pathogenesis of Crohn’s disease and may also have direct clinical applications in both diagnosis and therapy.

4.3.3. Immunopathology

Whatever the precise aetiology of the disease, numerous studies have confirmed the role of a constant stimulation of the mucosal and systemic immune systems to perpetuate the inflammatory cascade and lead to the gut lesions. Chronicity of inflammation seems to result from an interaction of the persistent stimulus of microbial antigens with genetically determined host susceptibility factors that determine the individual’s immune response, and/or mucosal barrier function\textsuperscript{95}. The pathogenesis could involve a series of steps, beginning with the breach of the mucosal barrier by infectious agents, or toxins. The defective barrier could expose lamina propria immune cells to the continuous presence of specific micro-organisms and/or resident luminal bacteria of the normal flora, bacterial products, or dietary antigens, which perpetuates the inflammatory cascade. Abnormal antigen presentation, with abnormal expression of HLA molecules by various cells, including epithelial intestinal cells, has been evoked. Immunological studies in the recent years have focused, however, on abnormalities in the cytokine secretion profile of T-cells, that contribute to differentiate Crohn’s disease from other inflammatory bowel diseases, such as ulcerative colitis. In Crohn’s disease, Th1 cells triggered by Interleukin-12 (IL-12) and producing IL-2 and Interferon γ (IFN-γ) are predominant and induce pro-inflammatory cytokine production, chemokine secretion and thus, activate cellular immunity through the recruitment and activation of macrophages\textsuperscript{112,113,114,115}. Tumor necrosis factor α (TNF-α) has been shown to be a key proinflammatory cytokine in the development of the lesions and in the persistence of IFN-γ production by Th1 cells. IL-6 levels are correlated with the severity of the disease and best predict relapses\textsuperscript{116}. Conversely, production of "anti-inflammatory" cytokines, such as IL-10, IL-4 and IL-13, seems deficient, or at least insufficient to counteract the pro-inflammatory loop of the immune response\textsuperscript{114,117}. These observations have served as rationale for new therapeutic attempts: IL-10 has been shown to suppress chronic granulomatous inflammation induced experimentally by bacterial cell wall polymers, and pilot clinical trials have shown the efficacy of chimeric monoclonal antibodies to TNF-α, and of IL-10, in patients with Crohn’s disease\textsuperscript{118,119,120,121,122,123}. It must be noted that Th-1-related mechanisms are those usually considered as efficient against mycobacterial agents. The continuous Th-1 stimulation could be an inappropriate but chronic response to mycobacteriae, unable to eradicate the offending microorganism, but leading to mucosal damage; alternatively, a relative success in killing the microorganism could be associated with genetically induced failure in producing those anti-inflammatory cytokines that could stop the
cellular immune response. Similarly to the observations of "lymphocytic" versus "lepromatous" forms of leprosy, it has been hypothesised that different presentations of Crohn’s disease, an aggressive fistulising form and an indolent obstructive form, could represent differing host immune responses to a common antigenic stimulus (possibly mycobacterial) and could provide a new and key insight into the pathogenesis of the disease.

4.4 Pathology

The earliest macroscopic lesions of Crohn’s disease appear to be tiny focal “aphthoid” ulcerations of the mucosa, usually with underlying nodules of lymphoid tissue. Sometimes these lesions regress; in other cases, the inflammatory process progresses to involve all layers of the intestinal wall, which becomes greatly thickened. Changes are most marked in the submucosa, with lymphoedema and lymphocytic infiltration occurring first, and extensive fibrosis later. Patchy ulcerations develop on the mucosa, and the combination of longitudinal and transverse ulcers with intervening mucosal oedema frequently creates a characteristic “cobblestone” appearance. The attached mesentery is thickened and lymphoedematous; mesenteric fat typically extends onto the serosal surface of the bowel. Mesenteric lymph nodes are often enlarged. The transmural inflammation, deep ulceration, oedema, and fibrosis are responsible for obstruction, deep sinus tracts and fistulas, and mesenteric abscesses, which are the major local complications.

Segments of diseased bowel are characteristically sharply demarcated from adjacent normal bowel – thus the name “regional” enteritis. Segmental lesions may be separated by normal areas (skip lesions). With reference to disease distribution in the gut a recent European collaborative study has shown that ileum alone is involved in about 10% of cases (ileitis); both ileum and colon are affected in about 60% (ileocolitis); and the colon alone is involved in about 30% (granulomatous colitis). Occasionally the entire small bowel (jejunoileitis) is involved, and rarely also the stomach, duodenum, or oesophagus.

Sarcoïd-type epithelioid granulomas in the intestinal wall and occasionally in the involved mesenteric nodes are pathognomonic, but since they are absent in up to 50% of patients, they are not essential to diagnose Crohn’s disease. Although they may represent a hidden clue to pathogenesis, they appear to have no definitive bearing on the clinical course.

While granulomas are helpful in distinguishing Crohn’s disease from other forms of inflammatory bowel diseases, when present, it is the chronic inflammation involving all layers of the intestinal wall which is most characteristic of Crohn’s disease. Both lymphocytes and macrophages are present in the granulomas and/or the cellular infiltrate. In active Crohn’s disease, mucosal T lymphocyte numbers appear reduced but the subset distribution is normal; activated macrophages and infiltrative monocytes, associated with giant cells and epithelioid cells in the granulomas, seem to be much involved in the pathogenesis of the lesions through the production of pro-inflammatory cytokines, lysosomal enzymes, oxygen free radicals, nitric oxide and extra-cellular
matrix components. Mesenteric lymph nodes show extensive infiltration of T-dependent areas with activated macrophages. Inflammatory cell turnover correlates closely with clinical and histological indices of disease activity\textsuperscript{126, 127}.

### 4.5 Clinical Features

Chronic diarrhoea associated with abdominal pain, fever, anorexia, weight loss, and a right lower quadrant mass or fullness are the most common presenting features\textsuperscript{128}. However, many patients are first seen with an “acute abdomen” simulating acute appendicitis or intestinal obstruction, both of which must be ruled out. Four patterns of regional enteritis occur most often:

1. inflammation, characterised by right lower quadrant abdominal pain and tenderness, mimicking appendicitis when acute;

2. obstruction, in which intestinal stenosis causes recurrent partial obstruction with severe colic, abdominal distention, constipation, and vomiting;

3. diffuse jejunoileitis, with both inflammation and obstruction resulting in malnutrition and chronic debility;

4. abdominal fistulas and abscesses, usually late developments, often causing fever, painful abdominal masses, and generalised wasting. Fistulas may be enteroenteric, enterovesical, retroperitoneal, or enterocutaneous.

Obstruction, fistulation, and abscess formation are common complications of inflammation; intestinal bleeding, perforation, and small bowel cancer develop rarely. A history of perianal disease, especially fissures and fistulas, can be elicited in about one third of patients. When colon alone is affected, the clinical picture may be indistinguishable from ulcerative colitis raising questions of differential diagnosis.

Extraintestinal complications of Crohn’s disease fall into three principal categories:

1. Complications that often parallel the activity of the intestinal disease and possibly represent acute immunological or microbiological concomitants of the bowel inflammation include peripheral arthritis, episcleritis, aphthous stomatitis, erythema nodosum, and pyoderma gangrenosum. These manifestations may be reported by over 1/3 of patients hospitalised with inflammatory bowel disease. They are twice as common when colitis is present as when disease is confined to the small intestine. When extraintestinal manifestations occur they are multiple in about one third of patients.

2. Disorders associated with inflammatory bowel disease but running an independent course include ankylosing spondylitis, sacroilitis, uveitis, and primary sclerosing cholangitis.
(3) Complications that relate directly to the disrupted physiology of the bowel itself are chiefly renal problems. Kidney stones result from disorders of uric acid metabolism, impairment of urinary dilution and alkalinisation, and excessive dietary oxalate absorption; urinary tract infections occur especially with fistulation into the urinary tract; and hydroureter and hydronephrosis may result from ureteral compression by retroperitoneal extension of the intestinal inflammatory process.

Other bowel related complications include malabsorption, especially in the face of extensive ileal resection or bacterial overgrowth from chronic small bowel obstruction or fistulation; gallstones, related to impaired ileal reabsorption of bile salts; and amyloidosis, secondary to long standing inflammatory and suppurative disease.
### Table 2. Comparative Summary

Pathological features in Crohn’s disease and paratuberculosis

<table>
<thead>
<tr>
<th>Lesion Location</th>
<th>Crohn’s Disease</th>
<th>Paratuberculosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>oesophagus and oral cavity</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>ileum and colon</td>
<td>Yes</td>
<td>Yes(^1)</td>
</tr>
<tr>
<td>mesenteric lymph nodes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>rectum, anus</td>
<td>Yes</td>
<td>Advanced cases(^2)</td>
</tr>
<tr>
<td>segmental</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Macroscopic Features</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>macroscopic appearance</td>
<td>Oedema of affected bowel wall, “garden hose” like appearance</td>
<td>Thickened bowel wall(^2)</td>
</tr>
<tr>
<td>parietal oedema</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>stenosis</td>
<td>Yes</td>
<td>Rare</td>
</tr>
<tr>
<td>perforation</td>
<td>Yes</td>
<td>Rare</td>
</tr>
<tr>
<td>fistula</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>pseudopolyps</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>mucosal aspect</td>
<td>cobble stone appearance</td>
<td>Corrugated(^2,3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Microscopic appearance</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>transmural involvement</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>fibrosis</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>lymphoid aggregates</td>
<td>Yes</td>
<td>Yes(^3)</td>
</tr>
<tr>
<td>granuloma</td>
<td>Yes (50%-70% of cases)</td>
<td>Yes</td>
</tr>
<tr>
<td>caseation</td>
<td>No</td>
<td>Usually not(^4)</td>
</tr>
<tr>
<td>fissures</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>visible acid fast bacilli</td>
<td>No</td>
<td>Yes(^5)</td>
</tr>
</tbody>
</table>

\(^1\) Ileum and jejunum are the initial and most frequent locations
\(^2\) not always in sheep
\(^3\) predominant feature in lymphocytic/paucimicrobial form
\(^4\) Varies with species
\(^5\) Scarce or absent in lymphocytic/paucimicrobial form
### Table 3. Comparative Summary

**Clinical Features of Crohn’s disease and paratuberculosis**

<table>
<thead>
<tr>
<th></th>
<th>Crohn’s Disease</th>
<th>Paratuberculosis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preclinical Stage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- symptoms and signs</td>
<td>Not known</td>
<td>Decreased milk yield</td>
</tr>
<tr>
<td>- incubation period</td>
<td>Not known</td>
<td>Minimum 6 months</td>
</tr>
<tr>
<td><strong>Clinical Stage</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- presenting symptoms and signs</td>
<td>Chronic diarrhoea</td>
<td>Chronic diarrhoea(^1)</td>
</tr>
<tr>
<td></td>
<td>Abdominal pain</td>
<td>Dull hair</td>
</tr>
<tr>
<td></td>
<td>Weight loss</td>
<td>Weight loss</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decrease in lactation</td>
</tr>
<tr>
<td><strong>Gastro-intestinal symptoms and signs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- diarrhoea</td>
<td>Chronic (3 weeks +)</td>
<td>Chronic(^6)</td>
</tr>
<tr>
<td>- blood in stools</td>
<td>Rare</td>
<td>Rare</td>
</tr>
<tr>
<td>- vomiting</td>
<td>Rare</td>
<td>No</td>
</tr>
<tr>
<td>- abdominal pain</td>
<td>Yes</td>
<td>No evidence</td>
</tr>
<tr>
<td>- obstruction</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td><strong>Extra-intestinal manifestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- polyarthritis</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>- uveitis</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>- skin lesions</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>- amyloidosis</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>- hepatic granulomatosis</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>- renal involvement</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td><strong>Clinical Course</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- remission and relapse</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

\(^1\) Not seen in sheep
5. Epidemiology and geographical distribution of both diseases

5.1 Epidemiology and geographical distribution of paratuberculosis in animals

Since its first description, paratuberculosis has been recognised world-wide. However, the difficulty in its diagnosis means that accurate studies concerning its actual distribution are not available. In Europe, studies were made in France in 1934 with a prevalence of 0.8% of bovines. Various surveys of abattoir cattle in England during the 1950’s suggested prevalence rates between 11-17%. Jørgensen (1965) found that the 2.3% of adult cattle slaughtered in Denmark were positive in culture and this figure increased to 9.8% in 1972. More recently, a survey was carried out in Belgium on 300 serum samples obtained from cattle that are representative of the bovine population of the Walloon part of the country. This survey made with an ELISA based on a recombinant peptide (a362) endowed with B-cell epitopes specific to Map indicated that the seroprevalence of paratuberculosis in that part of Belgium was 12%. In the USA, a national survey was performed in the 1980’s, by a bacteriological examination of over 7000 samples from different bovine abattoirs around the country. The infection was considered as present in 1.6% of all cattle and 2.9% of cull cows. In Spain, prevalence in cattle was estimated to be 1% of adult cattle in a slaughterhouse bacteriological survey and at 67% of herds by ELISA in the Basque country.

More recent data are available from prevalence studies in Belgium and the Netherlands. In both countries prevalence studies were conducted using the absorbed ELISA as the diagnostic tool. In Belgium the seroprevalence was found to be 17.4% of herds and 1.2% of individual animals. In the Netherlands the seroprevalence was 54.7% at the herd level and 2.5% at the individual animal level. In this latter study the test characteristics were taken into account when the true prevalences were calculated. The uncertainties in the characteristics with respect to sensitivity and specificity are responsible for large ranges in the calculated true prevalence: for example using a sensitivity and specificity of 30% and 99.5%, respectively, the estimated true prevalence at herd level is 70.6% and at animal level 6.9%. Using a sensitivity and specificity of 40% and 98.5%, respectively, the prevalences are 31.3% at the herd level and 2.7% at the animal level. Nevertheless these results show that paratuberculosis is a widespread problem. The differences in results between both studies can at least be explained in part by the differences in cattle populations tested in both countries: in Belgium the vast majority of herds tested were beef cattle herds whereas in the Netherlands the herds tested were dairy cattle herds.

Some studies have also been carried out in sheep. In Greece, 9.8% of ovines tested were positive to delayed-type hypersensitivity tests. In Spain, a study in the Region of Aragon by means of serological, bacteriological and pathological techniques...
identified 46.7% of flocks as infected\textsuperscript{140}. Within flocks, prevalence levels of affected animals ranging from 33\%\textsuperscript{141} to 46\%\textsuperscript{76} have been reported. In the Basque Country, prevalence in sheep was estimated by ELISA to be 32\% of flocks\textsuperscript{142}.

5.2. Epidemiology and geographical distribution of Crohn’s disease

A review of the literature suggests that Crohn’s disease is more prevalent in Western populations with northern European and Anglo-Saxon ethnic derivation, than in populations of southern Europe, Asia and Africa. However, when the Asian people migrate to urban-industrial societies of the West, they become as susceptible to the disease as the population of their host countries, suggesting environmental factors in the aetiology of Crohn’s disease\textsuperscript{143}.

There are many epidemiological studies of the incidence and prevalence of Crohn’s disease from Europe and America. The problem, however, is that most of the early studies were retrospective. They used different study designs (for example criteria of disease definition, case ascertainment, or the time period of investigation) and, with few exceptions (Aberdeen, Copenhagen, Leiden, Stockholm, Uppsala) were based upon the experience of specialised medical centres. The data they provided on the risk of disease in the population were confusing, and in some respects unreliable.

To overcome this problem, a group of clinicians and epidemiologists in Europe carried out an epidemiological survey of the incidence of inflammatory bowel disease (EC-IBD study) in 20 centres across Europe prospectively and simultaneously between 1991 and 1994\textsuperscript{144}. The project was a Concerted Action project of the Commission of the European Communities with the aim of investigating the north-south gradient in the risk of disease (incidence) using a standard protocol for disease definition, case ascertainment and data analysis. The study was conducted in the population of defined geographical areas ranging from Reykjavic, Iceland in the north to Heraklion, Greece in the south, and included regional case reviews and site visits for the quality control of data.

The results of this study are presented in Table 5. They show that the highest age and sex adjusted incidence rate for Crohn’s disease (per 100,000) was in Amiens (NW France) and Maastricht (the Netherlands), followed by Oslo (Norway), Iceland, and Copenhagen (Denmark). The lowest reported incidence was from Ioannina (NW Greece). The incidence was broadly similar for men and women.

However, recent epidemiological studies conducted in different regions of France, using a common methodology, showed that the prevalence and incidence of Crohn’s disease tended to be as high in southern parts of that country as in the previously considered “high incidence areas” of the North\textsuperscript{145} (see table 4 below).
Table 4. Standardised incidence of CIBD in Europe and in France

<table>
<thead>
<tr>
<th>Registry Region</th>
<th>Year</th>
<th>CIBD n</th>
<th>CD n</th>
<th>UC n</th>
<th>UCC n</th>
<th>AC n</th>
<th>Standardised Incidence*°</th>
<th>Estimated Incidence*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Northern Europe</td>
<td>83-96</td>
<td>2085</td>
<td>706</td>
<td>1379</td>
<td>-</td>
<td>-</td>
<td>5.0</td>
<td>9.8</td>
</tr>
<tr>
<td>Southern Europe</td>
<td>83-96</td>
<td>1346</td>
<td>477</td>
<td>869</td>
<td>-</td>
<td>-</td>
<td>6.3</td>
<td>11.4</td>
</tr>
<tr>
<td>Northern France</td>
<td>146</td>
<td>88</td>
<td>576</td>
<td>281</td>
<td>88</td>
<td>104</td>
<td>6.0</td>
<td>4.4</td>
</tr>
<tr>
<td>Northern France</td>
<td>147</td>
<td>88-90</td>
<td>1291</td>
<td>674</td>
<td>466</td>
<td>151</td>
<td>4.9</td>
<td>5.1</td>
</tr>
<tr>
<td>Central France</td>
<td>148</td>
<td>93-94</td>
<td>167</td>
<td>79</td>
<td>29</td>
<td>4</td>
<td>5.7</td>
<td>6.4</td>
</tr>
<tr>
<td>Western France</td>
<td>149</td>
<td>94-95</td>
<td>657</td>
<td>205</td>
<td>165</td>
<td>42</td>
<td>2.8</td>
<td>2.7</td>
</tr>
</tbody>
</table>

* n/100000/year ° incidence standardised for age and sex.
CIBD: chronic inflammation bowel diseases; CD: Crohn’s disease; UC: ulcerative colitis; UCC: unclassified chronic colitis; AC: acute colitis.

In summary, the EC-IBD study has produced an overall picture of the incidence of Crohn’s disease and its geographical distribution across Europe. It has further shown that the incidence of Crohn’s disease is 80% higher in the north than that in the south. The observed excess of incidence in the north did not seem to be explained by differences in tobacco consumption and education. The age-specific incidence rates per 100,000 show that the age group 15-24 were most at risk of coming down with the disease and the risk of disease in both sexes was broadly similar.

Similar North-South gradients in incidence have also been documented in North America. For example, the highest reported incidence of Crohn’s disease in the world is in Manitoba, Canada of 14.6 per 100,000 population per year\(^{150,151}\), followed by an incidence rate of 10 in Northern Alberta\(^{152}\), and of 7 cases per 100,000 population in Olmsted County, Minnesota\(^{153}\), 400 miles to the South of Manitoba. These are substantial differences and suggest that climate, diet, water supply or other environmental factors may be involved in the risk of this disease in different geographical areas of the world.
Table 5  Incidence rates (/100,000/year) and numbers of cases (in parentheses) aged 15-64 years for Crohn’s disease reported in the 20 centres included in the EC-IBD study 1991-94.

<table>
<thead>
<tr>
<th>Centre</th>
<th>Crude rate</th>
<th>Age Adjusted rate (95% CI)</th>
<th>Crude rate</th>
<th>Age Adjusted rate (95% CI)</th>
<th>Crude rate</th>
<th>Age Adjusted rate (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men</td>
<td>Women</td>
<td>Total</td>
<td></td>
<td>Men</td>
<td>Women</td>
</tr>
<tr>
<td>Northern Centres</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reykjavic (Iceland)</td>
<td>8.8 (15)</td>
<td>8.4 (5.5-11.3)</td>
<td>7.9(13)</td>
<td>7.2 (4.6-9.8)</td>
<td>8.4 (28)</td>
<td>7.8 (4.0-11.7)</td>
</tr>
<tr>
<td>Oslo (Norway)</td>
<td>7.6 (48)</td>
<td>7.6 (6.1-9.1)</td>
<td>8.2 (52)</td>
<td>8.3 (6.8-9.7)</td>
<td>7.9 (100)</td>
<td>7.9 (5.9-9.9)</td>
</tr>
<tr>
<td>Copenhagen (Denmark)</td>
<td>5.3 (20)</td>
<td>5.4 (3.8-7.1)</td>
<td>8.9 (34)</td>
<td>9.3 (7.3-11.4)</td>
<td>7.2 (54)</td>
<td>7.3 (4.7-10.0)</td>
</tr>
<tr>
<td>Dublin (Ireland)</td>
<td>4.8 (19)</td>
<td>4.5 (3.1-5.9)</td>
<td>6.5 (27)</td>
<td>5.9 (4.5-7.4)</td>
<td>5.7 (46)</td>
<td>5.2 (3.2-7.2)</td>
</tr>
<tr>
<td>Leicester (UK)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non Immigrants</td>
<td>1.7 (2)</td>
<td>1.6 (0.1-3.1)</td>
<td>6.6 (8)</td>
<td>6.1 (3.3-8.9)</td>
<td>4.2 (10)</td>
<td>3.8 (0.7-6.9)</td>
</tr>
<tr>
<td>Immigrants</td>
<td>8.3 (4)</td>
<td>9.4 (2.9-15.9)</td>
<td>2.0 (1)</td>
<td>1.7 (0.0-3.8)</td>
<td>5.0 (5)</td>
<td>5.6 (0.0-12.5)</td>
</tr>
<tr>
<td>Maastricht (the Netherlands)</td>
<td>8.1 (37)</td>
<td>8.3 (6.5-10.2)</td>
<td>10.1 (45)</td>
<td>10.1 (8.2-12.0)</td>
<td>9.1 (82)</td>
<td>9.2 (6.5-11.8)</td>
</tr>
<tr>
<td>Essen (Germany)</td>
<td>3.1 (17)</td>
<td>3.2 (2.2-4.2)</td>
<td>5.3 (29)</td>
<td>5.6 (4.2-6.9)</td>
<td>4.2 (46)</td>
<td>4.4 (2.7-6.1)</td>
</tr>
<tr>
<td>Amiens (NW France)</td>
<td>8.1 (29)</td>
<td>8.0 (6.0-9.9)</td>
<td>10.8 (39)</td>
<td>10.6 (8.4-12.7)</td>
<td>9.5 (68)</td>
<td>9.2 (6.3-12.2)</td>
</tr>
<tr>
<td>All Northern Centres</td>
<td>6.2 (191)</td>
<td>6.2 (4.2-8.1)</td>
<td>7.9 (248)</td>
<td>7.9 (5.9-9.8)</td>
<td>7.0 (439)</td>
<td>7.0 (4.2-9.8)</td>
</tr>
<tr>
<td>Southern Centres</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milan-Varese (Italy)</td>
<td>1.4 (2)</td>
<td>1.4 (0.1-2.6)</td>
<td>3.5 (5)</td>
<td>3.6 (1.5-5.6)</td>
<td>2.5 (7)</td>
<td>2.5 (0.1-4.9)</td>
</tr>
<tr>
<td>Crema-Cremona (Italy)</td>
<td>2.2 (5)</td>
<td>2.3 (0.9-3.6)</td>
<td>2.9 (6)</td>
<td>3.1 (1.5-4.7)</td>
<td>2.6 (11)</td>
<td>2.7 (0.6-4.8)</td>
</tr>
<tr>
<td>Reggio Emilia (Italy)</td>
<td>4.8 (10)</td>
<td>4.8 (3.1-6.5)</td>
<td>3.9 (11)</td>
<td>4.1 (2.5-5.7)</td>
<td>4.3 (25)</td>
<td>4.4 (2.1-6.7)</td>
</tr>
<tr>
<td>Florence (Italy)</td>
<td>2.4 (10)</td>
<td>2.6 (1.5-3.7)</td>
<td>4.0 (17)</td>
<td>4.1 (2.8-5.3)</td>
<td>3.2 (27)</td>
<td>3.3 (1.7-5.0)</td>
</tr>
<tr>
<td>Vigo (N.W. Spain)</td>
<td>7.8 (27)</td>
<td>7.3 (5.4-9.2)</td>
<td>3.1 (11)</td>
<td>2.8 (1.7-3.9)</td>
<td>5.4 (38)</td>
<td>5.1 (2.9-7.3)</td>
</tr>
<tr>
<td>Sabadell (N.E. Spain)</td>
<td>4.0 (10)</td>
<td>3.8 (2.2-5.4)</td>
<td>6.8 (17)</td>
<td>6.6 (4.6-8.7)</td>
<td>5.4 (27)</td>
<td>5.2 (2.6-7.7)</td>
</tr>
<tr>
<td>Braga (N. Portugal)</td>
<td>3.0 (5)</td>
<td>2.7 (1.1-4.3)</td>
<td>5.7 (10)</td>
<td>5.7 (3.4-8.0)</td>
<td>4.4 (15)</td>
<td>4.2 (1.3-7.0)</td>
</tr>
<tr>
<td>Ioannina (N.W. Greece)</td>
<td>1.2 (2)</td>
<td>1.1 (0.1-2.2)</td>
<td>0.6 (1)</td>
<td>0.7 (0.0-1.5)</td>
<td>0.9 (3)</td>
<td>0.9 (0.0-2.2)</td>
</tr>
<tr>
<td>Almada (S. Portugal)</td>
<td>1.9 (4)</td>
<td>1.9 (0.7-3.2)</td>
<td>3.3 (7)</td>
<td>3.3 (1.7-4.9)</td>
<td>2.6 (11)</td>
<td>2.6 (0.6-4.6)</td>
</tr>
<tr>
<td>Palermo, Sicily (Italy)</td>
<td>7.4 (6)</td>
<td>7.1 (3.2-11.0)</td>
<td>6.0 (6)</td>
<td>6.1 (2.9-9.3)</td>
<td>6.6 (12)</td>
<td>6.6 (1.6-11.5)</td>
</tr>
<tr>
<td>Heraklion, Crete (Greece)</td>
<td>7.6 (11)</td>
<td>7.5 (4.5-10.4)</td>
<td>2.0 (3)</td>
<td>2.1 (0.5-3.6)</td>
<td>4.7 (14)</td>
<td>4.8 (1.5-8.1)</td>
</tr>
<tr>
<td>Beer Sheva (Israel)</td>
<td>2.3 (5)</td>
<td>2.4 (0.9-3.8)</td>
<td>6.5 (14)</td>
<td>6.5 (4.2-8.9)</td>
<td>4.4 (19)</td>
<td>4.4 (1.7-7.2)</td>
</tr>
<tr>
<td>All southern centres</td>
<td>3.9 (101)</td>
<td>3.8 (1.9-5.8)</td>
<td>4.0 (108)</td>
<td>4.0 (2.0-6.0)</td>
<td>3.9 (209)</td>
<td>3.9 (1.1-6.7)</td>
</tr>
<tr>
<td>All Centres</td>
<td>5.1 (292)</td>
<td>5.1 (4.7-5.5)</td>
<td>6.1 (356)</td>
<td>6.1 (5.7-6.5)</td>
<td>5.6 (648)</td>
<td>5.6 (2.8-8.3)</td>
</tr>
</tbody>
</table>
5.3 Is the incidence of both diseases changing?

From 1950s to 1980s several centres reported considerable increases in the incidence of Crohn’s disease. Whereas, the latest studies have suggested that the increase in the incidence of Crohn’s disease in the north has slowed or reached a plateau\(^{154,155,156,157}\). The southern European centres have, however, continued to show an increase in annual incidence over the last several years\(^{158,159}\). This may reflect more sensitive diagnostic methods, greater case ascertainment or increasing urbanisation and industrialisation of southern European societies.

Data are not available on which to base a comparison of the incidence of paratuberculosis over time.

5.4 Is there a causal association between the geographical incidence/prevalence of Crohn’s disease and that of paratuberculosis?

If Crohn’s disease in humans is caused by simple contact and infection with Map strains originating from paratuberculosis infection in animals one would expect a causal association between the geographical incidence and prevalence of both diseases.

There are a number of problems with this assumption which merit caution and render conclusions difficult to interpret.

1. Lack of reliable data on incidence and prevalence of both diseases especially paratuberculosis

While information has recently become available on the incidence rates of Crohn’s disease in various population centres in Europe (Table 5) corresponding information on the incidence and prevalence of paratuberculosis in the regions of these centres is not available. Indeed, there are considerable difficulties in obtaining comparable data. It does seem clear however that paratuberculosis is extremely common in most parts of Europe (and the world) in both the cattle, sheep and goat populations. Those areas which are reputed to have a low prevalence of paratuberculosis have in general not been systematically examined to determine the prevalence of the disease. There are no areas where the disease has been conclusively shown to be absent in animals. The reported incidence of the disease, in all areas, are likely to be a fraction of the number of animals infected and shedding the organism.

2. Long incubation period.

If Map were to be involved in the aetiology of Crohn’s disease, it is possible, as in animals, that the exposure to the organism would have taken place many years before the appearance of clinical signs. Comparisons, therefore, would need to be made between current incidence in man and the incidence of paratuberculosis in the animal population ten or fifteen years ago. These data are simply not available.
In short, there are considerable problems in assessing a causal association between the two diseases based on the geographical incidence and prevalence of both diseases. These issues include the evident time lag before clinical signs, the multifactorial nature of both diseases, the use of vaccine for paratuberculosis in some regions, dietary habits in humans and the influence of migrations.
6. Diagnosis and control of paratuberculosis

6.1 Introduction

The diagnostic techniques that can be used to detect the disease are influenced by the stage of the disease as it has developed in the affected host and the prevalence in the herd\textsuperscript{160, 161, 162}. Control of the disease on the farm as well as to stop further spread of the disease by trading of infected animals largely depends on the recognition of young infected animals as early as possible. Detection of the infection of the host during this sub-clinical stage is complicated by the fact that the bacterium does not multiply rapidly and is therefore difficult to detect in faeces. There is little or no immune response at this stage. Serum antibodies are absent and even though a delayed type hypersensitivity response (DTH) occurs early in infection, it is not as significant as in (bovine) tuberculosis and the response wanes as the infection progresses.

In the clinical stage, serum antibodies are detectable in an ELISA assay and the bacterium can be cultured from faecal samples, though the organism may also be cultured before clinical signs appear. The sensitivity of both tests increases rapidly at this stage. Fig. 2 (adapted from Collins, 1998\textsuperscript{163}) gives an illustration of the usefulness of the respective tests in cattle infected in early life at different stages of the disease. Even though this picture is valid in general, there is a great variety of different responses among individual animals, especially in the case of the paucibacillary form of the disease in sheep.

![Figure 2: Typical responses to diagnostic tests in animals infected in early life -](image-url)
The available tests can be divided into two groups. The first group of tests is aimed at the detection of the causative agent. The tests are: microscopic examination of faecal smears (Ziehl-Neelsen stain) though this is subject to the limits stated below, culture of the organism from faecal samples and the detection by polymerase chain reaction (PCR). Both these tests depend on the presence of the organism in faeces which is more likely as the disease progresses. The second group consists of the immunological tests. These are: the (absorbed) ELISA, the complement fixation test (CFT), the agar gel immunodiffusion test (AGID) and the delayed type hypersensitivity test (intradermal or interferon γ test).

6.2 Detection of the causative agent

6.2.1 Microscopical examination

The microscopic examination of (Ziehl-Neelsen stained) faecal smears is a rapid, economical way of obtaining a diagnosis. The diagnosis depends on the presence of clumps of small acid fast bacteria, as these can be shed intermittently. The presence of single acid fast bacilli from environmental origin in faecal samples is quite common and makes a diagnosis sometimes difficult and not completely specific. The test has a low sensitivity in early stages of the disease, but when the animal reaches the clinical stage, the test reaches virtually 100% sensitivity.

6.2.2. Cultural methods.

The traditional culture of Map from faeces is, as the disease progresses, the most sensitive test available and has a 100% specificity and is therefore regarded as the "gold standard". However, the test is very labour-intensive, time consuming and therefore expensive. The test itself is not standardised and the laboratory proficiency varies considerably. The decontamination procedure is one of the variables in the procedure but an essential step in all methods used\textsuperscript{164}. Since culturing can take up to six months to complete, it is crucial to eliminate the fast growing bacteria from the samples being tested. At present there are two basic methods in use for the culture of Map from clinical specimens: the method using oxalic acid and NaOH for decontamination and Löwenstein-Jenssen medium for growth and the method using hexadecylpyridinium (HPC) for decontamination in combination with Herrold's Egg Yolk Medium (HEYM) for growth. Both media contain mycobactin. Colonies can be recovered after 4-24 weeks of culture. Confirmation of the identity of the colonies was usually done by transferring them onto media with and without mycobactin. Incubation would take another 4 weeks and the mycobactin dependant colonies would be regarded as being Map. Nowadays the confirmation can be done within a day by the PCR amplification of the IS900 element, which is specific for Map\textsuperscript{165}.
Because culture is often used as a gold standard to estimate the sensitivity of other tests, its lack of standardisation makes the interpretation of results obtained (e.g. ELISA sensitivity, prevalence studies) by different laboratories extremely difficult.

Another, more rapid technique for the isolation of *Map* employs the use of a radiometric based detection system, the Bactec 460\textsuperscript{166}. Growth of mycobacteria is measured by the release of $^{14}\text{CO}_2$ from palmitate by bacterial metabolism. However as this system is radiometrically based, it is not feasible to use in some laboratories and is phased out in others.

Recently three other, fluorescence-based rapid methods were introduced, the Bactec 9000 and the MGIT system (Becton Dickinson) and the MBBact system (Organon Technika). Initial experiments in which these methods were tested on faecal samples, suffered from severe problems with overgrowth by other bacteria (spore forms and fungi). Thusfar, an evaluation of these methods could not be made.

### 6.2.3. Polymerase Chain Reaction (P.C.R.)

The PCR for the detection of *Map* uses the IS900 insertion sequence as target sequence. This insertion sequence is specific for the bacterium and is present in 14 to 18 copies in the genome, making it an abundant target\textsuperscript{167}.

The technique of the polymerase chain reaction (PCR) offers an attractive alternative for the traditional cultural methods. It is not only a more rapid test (several days as opposed to six months) it can also offer high levels of specificity. However, great care has to be taken with regard to the specificity of the primer sets used in the PCR and the identity of the amplified product needs to be confirmed not only by size but also by DNA hybridisation.

However a high level of sensitivity is rarely attained due to problems encountered in sample preparation. Reduced sensitivity can result from inefficient extraction of the mycobacteria from the sample, particularly when small numbers of organisms are involved, or as a consequence of the presence of inhibitors of PCR. Different inhibitors are present in different types of sample but examples include large amounts of irrelevant DNA, polysaccharides, bile salts, etc. Different types of samples pose different barriers to extraction and PCR. Unfortunately, faecal samples belong to the samples that are very difficult to process. Recent improvements in the method, indicate that it is possible to reach a sensitivity of 50 bacteria per gram of faeces which is similar to that of culture\textsuperscript{168}. The extraction procedures are time consuming and require well trained technicians. As is the case with faecal culture only a limited number of samples can be processed. This makes implementing the PCR as a routine operation in a diagnostic laboratory rather difficult. Recently, the application of the IS900 PCR assay to blood and other tissues from sheep with clinical paratuberculosis raise some hope for the development of PCR as a routine technique. This PCR has particular advantages for the diagnosis of paratuberculosis because it can detect, for example, strains that are refractory to culture, for example certain types of sheep strains\textsuperscript{169}. PCR can also be used for the analysis of tissue samples from Crohn's disease patients. In addition, it is a very rapid method for the identification of strains isolated from suspected samples.
Recent communications mention the occurrence of false positive reactions with other mycobacteria. Therefore the specificity of the PCR and/or the primer sets being used will have to be established for the different types of samples to be tested.

6.3 Detection of an immune response to M. avium subsp. paratuberculosis

Despite the fact that microbial culture is regarded as the most sensitive test for the detection of paratuberculosis, because the test is so labour intensive and requires an extremely long incubation time, its usefulness as a test in a certification and/or eradication programme is limited.

For such purposes a serological test such as an ELISA, would be more suitable. These tests are fast, economical and, in fact, the only kind of tests that have the capacity to support a large scale testing programme. However, as can be seen from Figure 2, the antibody response (ELISA, CFT) rises at a late stage of the disease and is not detectable in the early stages. The ELISA will have a sensitivity rising from almost zero at the early stages of disease to virtually 100% when the animal reaches the clinical stage. The test is therefore only suitable for use on older cattle and is normally used on animals older than 2 years or sometimes only on animals older than 3 years. Furthermore, not all infected animals will give a measurable antibody response at an older age, but may be shedding the bacterium and be infectious to younger animals. As is the case for all mycobacterial infections, the overall sensitivity of the ELISA is rather low. Estimates for the sensitivity of the ELISA are highly variable, due to the testing of different age groups in the various studies. In addition, local differences in the load of environmental mycobacterial can contribute to differences in specificities obtained with the ELISA. This implies that using an ELISA at a certain time point will not identify all infected animals within the herd or guarantee the status of an individual animal.

6.3.1 The complement fixation test

The complement fixation test has been the most widely used standard test for paratuberculosis in cattle. The test allows the processing of a large number of samples and has a sufficiently high sensitivity to be used on clinical cases. A large number of different test protocols and different antigens are used world-wide and unfortunately the outcome of the test depends also on the interpretation of the person performing it. In general, the test lacks a sufficient sensitivity (and in many cases specificity) to be used as a reliable tool for the identification of infected animals.

Despite the fact that the outcome of the test gives no guarantee about the status of the individual animal, the CFT test is often the only test demanded for import/export of cattle within Europe.
6.3.2 The absorbed ELISA

The convenience of sample collection, rapid laboratory turnaround time and low cost have made an ELISA the preferred test for herd analysis. In general, the detection of serum antibodies against *Map* is achieved using different crude fractions of the bacterium; lipoolarabinomannan (LAM) or PPD's. False positive results usually occur as a result of cross reactions with related bacteria of the *Corynebacterium-Mycobacterium-Nocardia* group, or in countries where bovine tuberculosis is endemic. The occurrence of false positives is therefore also geographically dependant. Another problem arises from the use of vaccination against paratuberculosis, often needed to aid affected farms in their survival, as this results in serologically positive animals.

The specificity of the test is increased in the so-called absorbed ELISA by absorption with sonicates from other (environmental) mycobacteria, like *M.phlei* or *M.vaccae*. Since the commercial absorbed ELISA has become available, it has become the most widely used serological test for paratuberculosis in cattle. Another approach to avoid the occurrence of ELISA false positive results would be the use of *Map* specific recombinant antigens. To date only one of these antigens (peptide a362) has been described and used in an ELISA. Whereas this a362-ELISA seems promising, it needs further validations on a larger scale.

Reports on the sensitivity of the absorbed ELISA are contradictory. As mentioned above, they depend on the standard used (faecal culture, pathology etc.) to calculate the relative sensitivity and on the animals that are tested. Since serum antibodies become more abundant in the later stages of the disease, using the ELISA in a herd or group of animals where the disease has been present for a longer period will result in a reasonable sensitivity. However the test gives a very low sensitivity in young, recently infected animals and can therefore not be used to detect the disease on a farm where spread of the disease has just commenced. Therefore, the test would only be useful in herd certification programmes where there are a sufficient number of older animals present.

Diagnosis of paratuberculosis is usually based on the combined results of faecal culture and the absorbed ELISA. In the Netherlands and other countries, experimental certification protocols based on alternate faecal culturing and testing by an absorbed ELISA are being discussed. Both these tests, however, have their own problems: faecal culturing is slow, labour intensive and expensive and the ELISA lacks sufficient sensitivity, especially for the final stage of eradication.

6.3.3 Agar-gel-immuno-diffusion test (AGID)

The agar gel immuno-diffusion test can be used for the detection of paratuberculosis in a variety of different animals such as cattle, sheep, goats and deer. The methods employed in the different laboratories are variable and the antigens used are not specific for *Map*.

The relatively low cost of the AGID make this test a very attractive test for use in small ruminants. The AGID-test is, for example, the approved test for use in small ruminants, in fact the only approved test in goats, in the Australian National Johne’s
Disease Program. Like the ELISA, the AGID is based on the detection of antibodies against Map. Therefore it has a relatively low sensitivity in the early stages of the disease, but becomes more useful in later stages.

The AGID has been used mainly in small ruminants (sheep and goats). Its sensitivity is lower than ELISA test and, as in the former, is closely related to the immunopathological forms of the infection. Sheep and goats with focal and tuberculoid forms (non-clinical infections) are usually negative\(^{178}\). Of clinical cases, sheep and goats with multibacillary forms are positive to AGID whereas those showing lymphocytic forms are usually negative\(^{75}\). Due to these features, in general, the sensitivity of the AGID test is variable, depending on the group of investigated animals\(^{179,180,181}\).

### 6.3.4 Cellular Immunity Tests

As in leprosy and other mycobacterial diseases, a spectrum of immune responses occurs in Map infection (see also Fig 2). Early, or subclinical cases, have immune responses dominated by T cell-driven cellular responses, while more chronic, clinical cases are dominated by antibody responses. Therefore an optimal diagnosis of paratuberculosis would require a combination of cellular and antibody tests in order to identify both early and late cases - either of which may be missed by one of these tests used independently. However, the cellular response is less pronounced than in the case of bovine tuberculosis, where the intradermal test is still the most reliable test.

Cellular immunity tests can be performed in vivo or in vitro, using respectively the intradermal test or the gamma-interferon assay. Both tests are performed using avian purified protein derivative (PPD) or johnin (the paratuberculosis equivalent) to stimulate the response. In the intradermal test, skin thickness is measured before and 72 hours after injection with PPD. An increase in thickness of more than 2mm is regarded as a positive reaction. The gamma-interferon assay is performed by stimulating aliquots of heparinised blood with PPD and the subsequent release of gamma-interferon is measured in an ELISA\(^{182}\). However as PPDs are crude steam-sterilized mycobacterial culture filtrate extracts containing many cross-reacting antigens with related bacteria of the Corynebacteria-Mycobacteria-Nocardia group\(^{183}\), sensitisation to avian-PPD or johnin is very common in animals and therefore interferes with the specificity of both tests and makes interpretation of the results more difficult\(^{184}\). Moreover, as it has been mentioned above, there is a correlation between the positivity to cellular tests and animals showing focal-tuberculoid pathological forms. These are non clinical and non-shedding animals\(^{73}\). This results in a decreased sensitivity of the tests and reduces their value compared to the much cheaper ELISA.

### 6.4 Treatment of paratuberculosis in animals

Treatment of paratuberculosis in animals is not a feasible option. However, since the first description of the use of streptomycin in the treatment of 4 cows with Johne's
disease\textsuperscript{185}, there have been at least 14 reports of the use of conventional anti-
tuberculous and anti-leprosy drugs in the treatment of \textit{Map} infection in
animals\textsuperscript{186,187,188,189,190,191,192,193,194,195,196,197,198}. The animals tested included adult
cattle and calves, sheep, goats and experimentally infected rabbits. The drugs used
were streptomycin, isoniazid, clofazimine, rifampicin, ethambutol, pyrazinamide and
dapsone, either as single agents or in combination\textsuperscript{199}. In general, the number of
animals in these studies was small and the scope of the work was limited by the cost of
the drugs. Overall, the results of treatment were very similar. Where single agent
therapy was used, either no effect or a transient clinical improvement with a reduction
in faecal shedding was seen. Clinical improvement, if it occurred, usually lasted only a
few weeks and was inevitably followed by relapse, either on treatment or after
stopping the drug. The clinical and microbiological responses to drugs used in
combinations such as streptomycin, isoniazid and rifampicin, were more marked and
more prolonged than with single agent therapy, but cessation of faecal shedding of
\textit{Map} and the eradication of the infection were never convincingly achieved, and
persistence of disease and relapse occurred in the majority of these studies.
None of the above reports referred to randomised controlled trials of these agents in
experimentally or naturally infected animals so the results should be treated with
cautions.

6.5 Vaccination against paratuberculosis

Vaccination against paratuberculosis in cattle was first introduced in 1926 by Vallee
and Rinjard\textsuperscript{200}. The vaccination was performed by the subcutaneous injection of living,
unattenuated, paratuberculosis bacilli and was administered at 1-30 days of age,
subcutaneously in the brisket, where the vaccinal nodule is less obtrusive.
Revaccination was not recommended. Since then vaccines have been used in other
species, mainly sheep\textsuperscript{3,201,202,203}, involving subcutaneous administration in both young
(15 days to several months old) and adult animals. Many different formulations of the
vaccine have been evaluated, using living bacteria of both unattenuated and attenuated
strains, heat-killed organisms as well as disrupted fragments of \textit{Map}.

At present, according to the guidelines of the specifications of the Office International
des Epizooties (O.I.E.) the vaccines may contain live attenuated or killed bacteria
incorporated with an adjuvant or freeze dried and adjuvanted on reconstitution\textsuperscript{204}. However, because of the controversial reputation of \textit{Map} and the unknown
consequences of attenuated strains entering the food chain, the use of live vaccines is
not allowed in several countries (e.g. the Netherlands).

The use of vaccination is still under debate. In the opinion of some authors\textsuperscript{201,203,205},
vaccination is the best way to control the infection, especially in sheep and goats
though others conclude that vaccination alone is not sufficient to control
paratuberculosis and that husbandry and other control measures are necessary to obtain
maximum benefits. Since these changes in management coincide with the start of the
vaccination programme, the effect of the vaccination itself is often difficult to assess.
Clinical disease can still occur for several years after the start of vaccination on a
farm\textsuperscript{206} though several studies have noted the disappearance of clinical cases several
months following the vaccination of adult animals\textsuperscript{201,207,208}. However there is a
consensus that vaccination will reduce the number of animals with clinical disease, decrease the number of excretors and the level of excretion and therefore the number of animals with detectable intestinal infection\textsuperscript{209}.

In experimental studies\textsuperscript{203}, it has been observed that vaccination does not prevent infection but modifies the course of the disease and the pathology towards tuberculoid and regressive forms containing few (or undetectable) bacteria.

An important disadvantage is that vaccinated animals will respond positively to routine serodiagnostic tests for paratuberculosis\textsuperscript{210,211}. Thus, faecal culture remains the only available test to recognise infected animals though the PCR can be used in animals vaccinated using inactivated vaccines. However, because of the reduction in the excretion it will be more difficult to recognise the remaining carriers. Vaccinates must not be regarded as free of paratuberculosis and, in a certification programme, vaccinated herds should be treated as infected herds. A Dutch report states that vaccination does not reduce the overall prevalence of infection in a herd\textsuperscript{212}.

The sensitisation caused by vaccination not only affects the diagnosis of paratuberculosis. Vaccinated animals also become sensitised to bovine PPD used in the intradermal test in control and eradication programmes for bovine tuberculosis\textsuperscript{213}. Comparative skin tests using bovine PPD and johnin or avian PPD can be used to differentiate between reactions to \textit{M. bovis} infection and reactions caused by the vaccination\textsuperscript{214}. However it was shown that in some cases in vaccinated animals, the bovine reaction was greater than the avian reaction\textsuperscript{215}, thus leading to false positive reactions for tuberculosis. This limits the large scale use of the available vaccines in regions where bovine tuberculosis is endemic.

Another undesirable feature of vaccination is the development of an inflammatory swelling and a subsequent fibrocaseous nodule at the site of inoculation. Similar effects are possible in the case of accidental self-injection by the practitioner which could lead to severe local reactions, though these are not commonly reported.

In several countries vaccination has been used in order to control the disease. The adoption of a vaccination programme should be considered in heavily infected herds, in which the veterinary advisor considers adequate control will not be achieved by improved calf rearing hygiene alone. This will prevent considerable losses to the farmer and aid in his economical survival\textsuperscript{216}. 
6.6 Control and eradication programmes

In the light of the high prevalence of paratuberculosis, the significant economic losses caused by the disease and the uneasiness caused by a possible link with Crohn’s disease, attempts are being made in several countries to control paratuberculosis. In Australia, a large scale Market Assurance Programme focussed at cattle, sheep as well as goat herds is being set up and in other countries e.g. the Netherlands more experimental trials are being carried out to gain experience for a nationwide programme. The control programmes being developed not only differ from country to country but their design also heavily depends on the species the programmes are focussed on. For example, using faecal culture as a routine diagnostic test is for dairy cattle farmers an option, whereas the same test for the farmer with a goat or sheep flock (much larger number of animals, lower profits per animal and lower value of the animal itself) is not an economic option.

Indeed, for controlling the disease in small ruminants, vaccination, could be the only affordable alternative at present. Field trials using vaccination of small ruminants have been quite successful in removing clinical disease from the herds217. Vaccination has been used in small ruminants in Greece, Spain, UK and Iceland.

For control and eradication programmes, designed to be used in dairy cattle herds, to be successful, it is widely accepted that at the same time extensive husbandry measures should be taken in combination with intensive diagnostic testing. Husbandry measures have two objectives: first, to prevent further spread of a possible infection within a herd and second, to prevent introduction of the infection into a free herd. For the first objective, prevention of infection of young, newborn animals is very important. The introduction of clean calving pens, separate housing of young and older animals, feeding colostrum/milk from their own mother only etc. are very important rules. For the second objective it is very important to keep a closed herd. This involves not purchasing any animals from farms with an unknown history with respect to paratuberculosis but also not spreading manure as fertiliser coming from other farms. Methods to disinfect *Map* contaminated slurry by the addition of formalin or calcium cyanamide have also been described218.

However, the diagnostic tests remain the weak link in any conceivable control programme. All available tests, as discussed above, lack sufficient sensitivity to give any warranty about the paratuberculosis status of an individual animal at a single time point and young infected animals, which are most often traded, can easily escape testing. Nevertheless, available diagnostic tests like the absorbed ELISA or faecal culture, can be used in certifying the paratuberculosis status of a herd, even though the test has limited value for certifying the individual animal. This can be done by testing only the older animals within a herd and when positives are found the herd can be classified as positive. Repetitive testing will give, with each round of testing, more certainty about the true status of the herd.

In a prototype control programme, diagnostic testing is aimed at identifying infected herds and at certifying herds to be free of paratuberculosis. Isolating positive herds
(e.g. ban from trading) will stop further spread of paratuberculosis. Subsequently a test-and-cull programme should be used to eradicate the disease and replacement stock can be bought from certified free herds. In order to certify herds free of paratuberculosis, numerous rounds of testing over a period of at least 7-8 years may be needed.

Figure 3: Schematic diagram of a paratuberculosis control programme

Recent experience in the Netherlands\textsuperscript{219} with a small scale experimental certification programme showed, however, that even when herds with no known history of paratuberculosis were tested using faecal culture as the diagnostic test, positive farms were still being identified after five rounds of testing at six months intervals. This indicates that, with the test used, positive animals could be missed several times. In fact, fifty percent of the motivated and enthusiastic farmers, who entered the voluntary programme three years earlier ended up in the ‘positive’ category. Such farms will have to invest in husbandry changes and expensive diagnostic tests to participate in a test-and-cull programme which will take at least ten years before they will be eligible to enter a new certification programme to obtain free status. Experiences like this explain why there is, at present, less optimism about the
feasibility of rapid control programmes for paratuberculosis without the prior development of better diagnostic tests.
7. **M. avium ssp paratuberculosis** infection in humans.

7.1 Detection of Map in Crohn's disease by culture and PCR.

Mycobacteria and cell wall deficient organisms were first isolated from tissues from patients with Crohn's disease in the 1970's \(^{220}\). In the following decade the isolation of *Map* from chronically inflamed intestine of human patients was reported \(^{221}\). In this context, culture means the ability eventually to isolate colonies in conventional solid or liquid media with the morphological, phenotypic and biochemical characteristics of very slow growing, mycobactin dependent, bacillary-form *Map*, which could then be subcultured and maintained in the laboratory. Three techniques have been used to detect the organism in patients with Crohn's disease; culture, culture followed by PCR, and PCR applied to resected bowel tissue.

Using culture, *Map* and several other species of mycobacteria, such as *M. avium* complex, *M. kansasii*, *M. chelonei* and *M. fortuitum* were isolated by several research workers but only in up to 5% of people with Crohn's disease and often after incubation for many months or years \(^{222}\) \(^{223}\) \(^{224}\) \(^{225}\) \(^{226}\) \(^{227}\) (see Table 6). In many of these reports, spheroplast forms were obtained, some of which appeared from subsequent studies to be mycobacteria. Innoculation of *Map* isolated from a patient with Crohn’s disease has caused granulomas of the distal small intestine in goats following oral administration \(^{228}\) and hepatic and splenic granulomas in mice \(^{229}\) following intraperitoneal and intravenous injection.

The application of IS900 PCR to long term cultures raised the detection rate of *Map* in Crohn's disease gut to 30% \(^{230}\) \(^{231}\) (Table 7).

IS900 PCR applied directly to DNA extracts of full thickness surgically resected gut samples reported the presence of *Map* in about two thirds of people with Crohn's disease in 1992 \(^{232}\). This was the first study directly on intestinal tissues, since when there have been eighteen peer reviewed reports (see Tables 8 and 9) of similar studies using a wide variety of sample processing and PCR procedures, in which nine could identify *Map* in Crohn's disease some or most of the time \(^{233}\) \(^{234}\) \(^{235}\) \(^{236}\) \(^{237}\) \(^{238}\) \(^{239}\) \(^{240}\) \(^{241}\) and nine could not \(^{242}\) \(^{243}\) \(^{244}\) \(^{245}\) \(^{246}\) \(^{247}\) \(^{248}\) \(^{249}\) \(^{250}\), though these include more recent work. A recent study from Sweden \(^{251}\) employed a broad range PCR to amplify 16S rDNA in eubacteria reported MAC but also *Helicobacter* spp., *Listeria monocytogenes* and *Escherichia coli* in three of five surgical samples from Crohn's disease patients.

Several reasons have been suggested to account for the conflicting results on the PCR detection of *Map* in Crohn's disease such as the low abundance of the primary specific pathogen. In addition, it is considerably more difficult to isolate chromosomal DNA from mycobacteria than it is from other bacteria in general \(^{252}\). It has also been proposed that *Map* in Crohn's disease (or in sheep with the paucibacillary form of paratuberculosis) may not be a conventional spheroplast and may exist as a tough protease-resistant phenotype \(^{253}\). However, this has not been tested experimentally. It has also been reported that optimal access to target *Map* DNA requires the inclusion of a mechanical disruption step by vibrating the sample lysate in a slurry of silica and
ceramic particles using the Hybaid Ribolyser system or bead beater. The results of using these more recently optimised methods confirm the presence of *Map* in Crohn's disease tissue. *Map* has also been isolated from a single case of a patient with a non-tuberculous cervical lymphadenitis resistant to anti-TB treatment which preceded the onset of typical Crohn's disease by five years.

A system for the detection of *Map* has recently been developed which comprises a ten week incubation of a decontaminated tissue extract in an improved liquid culture medium (MGIT Becton Dickinson) followed by IS900 PCR on the culture. The results to date have identified *Map* in 6 of 7 full thickness surgical samples of intestinal wall from patients with Crohn's disease, and not in normal intestine. Using the same system of MGIT liquid culture followed by IS900 PCR on the culture, these researchers have also isolated *Map* from the centrifugal pellets (but not the cream fractions) of samples of breast milk obtained from two mothers with Crohn's disease who had recently given birth and not from the breast milk of five healthy women. The isolation of *Map* from the breast milk of women with Crohn's disease suggests that in humans as in animals, *Map* infection can be systemic.

Discrepancies, experimental difficulties and laboratory to laboratory variation have also surrounded the PCR detection of other low abundance bacterial pathogens particularly in the chronically inflamed disease tissues of people with tuberculosis, Lyme disease, brucellosis and lymphocytic leprosy. It seems clear, however that *Map* is present in the intestines of at least a proportion of Crohn’s disease patients but also, at a lower rate, in a proportion of apparently healthy controls.

**Table 6. Isolations of Map on culture media**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Total no examined</th>
<th>Crohns Patients</th>
<th>Controls</th>
<th>Method</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ref. 222</td>
<td>14</td>
<td>3/14</td>
<td>Not included</td>
<td>Culture for 18 months</td>
<td>Isolations of mycobactin dependent mycobacteria</td>
</tr>
<tr>
<td>Ref. 223</td>
<td>30</td>
<td>1/30</td>
<td>Not included</td>
<td>Culture from colonic material for 16 weeks confirmed by biochemical characteristics</td>
<td></td>
</tr>
<tr>
<td>Ref. 224</td>
<td>82</td>
<td>4/82</td>
<td>1/55</td>
<td>Culture from surgically resected tissue 1 confirmed as <em>Map</em></td>
<td>4 other mycobacteria isolated</td>
</tr>
<tr>
<td>Ref. 225</td>
<td>1</td>
<td>Not included</td>
<td>Culture <em>Map</em> confirmed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ref. 226</td>
<td>66</td>
<td>1/66</td>
<td>Not included</td>
<td>Culture <em>Map</em> confirmed</td>
<td>3 other mycobacteria isolated (fortuitum and 2 unknown)</td>
</tr>
<tr>
<td>Ref. 240</td>
<td>86</td>
<td>8/24</td>
<td>5/22 UC 1/40 non IBD</td>
<td>Faecal culture</td>
<td>PCR was also performed (see table 8) but both PCR and culture were not performed on all samples</td>
</tr>
<tr>
<td>Ref. 227</td>
<td>5</td>
<td>1/5</td>
<td>Not included</td>
<td>Culture from surgically resected tissue for 2.5 months</td>
<td></td>
</tr>
</tbody>
</table>
### Table 7. Detection of Map by PCR on culture media

<table>
<thead>
<tr>
<th>PCR on Culture</th>
<th>Reference</th>
<th>Total no examined</th>
<th>Crohns Patients</th>
<th>Controls</th>
<th>Method</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ref. 230</td>
<td>29</td>
<td>6/18</td>
<td>1/11</td>
<td>IS900 PCR</td>
<td>Other mycobacteria were also detected</td>
</tr>
<tr>
<td></td>
<td>Ref. 231</td>
<td>30 cultures examined</td>
<td>6/17 positive for Map</td>
<td>0/13</td>
<td>IS900 PCR</td>
<td>Mycobacterial DNA also detected in both CD and control tissues</td>
</tr>
</tbody>
</table>

### Table 8. Detection of Map by PCR on tissue samples

<table>
<thead>
<tr>
<th>PCR on tissue</th>
<th>Reference</th>
<th>Total no examined</th>
<th>Crohns Patients</th>
<th>Controls</th>
<th>Method</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ref. 232 above</td>
<td>103</td>
<td>26/40</td>
<td>6/63</td>
<td>PCR IS900 on surgically resected tissues</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ref. 233</td>
<td>62</td>
<td>11/24</td>
<td>5/38</td>
<td>PCR IS900 on fresh and paraffin embedded surgically resected tissues</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ref. 234</td>
<td>53</td>
<td>13/18</td>
<td>10/35</td>
<td>PCR IS900 on surgically resected tissues</td>
<td>Some controls were patients with undiagnosed intestinal disease</td>
</tr>
<tr>
<td></td>
<td>Ref. 235</td>
<td>61</td>
<td>4/31</td>
<td>0/30</td>
<td>PCR IS900 on surgically resected tissues</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ref. 236</td>
<td>35</td>
<td>2/9</td>
<td>2/15 UC 0/11 non IBD</td>
<td>PCR IS900 on colon biopsy samples</td>
<td>Several biopsies tested from different parts of the colon for each subject. Two (1CD+1UC) were positive from more than one site..</td>
</tr>
<tr>
<td></td>
<td>Ref. 237</td>
<td>44</td>
<td>10/10</td>
<td>11/18 UC 14/16 controls</td>
<td>PCR IS900</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ref. 238</td>
<td>61</td>
<td>10/26</td>
<td>4/35</td>
<td>PCR IS900 on paraffin wax embedded tissues</td>
<td>PCR Amplification was repeated – only slight reactions seen after the first amplification (40 cycles)</td>
</tr>
<tr>
<td></td>
<td>Ref. 239</td>
<td>74</td>
<td>17/36</td>
<td>2/18 UC 3/20 non IBD</td>
<td>PCR IS900</td>
<td></td>
</tr>
</tbody>
</table>
### Table 8
**Detection of Map by PCR on tissue samples**

<table>
<thead>
<tr>
<th>PCR on tissue</th>
<th>Total no examined</th>
<th>Crohns Patients</th>
<th>Controls</th>
<th>Method</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ref. 240</td>
<td>75</td>
<td>15/17</td>
<td>9/18 UC 1/40 non IBD</td>
<td>IS 900PCR-DEIA</td>
<td>Culture was also performed (see table 6) but both PCR and culture were not performed on all samples</td>
</tr>
<tr>
<td>Ref. 241</td>
<td>12</td>
<td>8/8</td>
<td>2/2 UC 0/2 colonic cancer</td>
<td>PCR IS900 on ileal mucosa</td>
<td></td>
</tr>
<tr>
<td>Ref. 251</td>
<td>22</td>
<td>3/11</td>
<td>0/11</td>
<td>PCR</td>
<td>Mycobacteria (PCR was not specific for map). The 3 positive were 3 of 5 taken surgically. Others were removed by endoscope</td>
</tr>
</tbody>
</table>

### Table 9. Failure to detect Map by PCR on tissue samples

<table>
<thead>
<tr>
<th>PCR on tissue</th>
<th>Total no examined</th>
<th>Crohns Patients</th>
<th>Controls</th>
<th>Method</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ref. 242</td>
<td>143</td>
<td>0/68</td>
<td>0/49 UC 1/26 non IBD controls</td>
<td>Fluorescent PCR IS900 on intestinal tissue samples</td>
<td></td>
</tr>
<tr>
<td>Ref. 243</td>
<td>72</td>
<td>0/36</td>
<td>0/13 0/23</td>
<td>PCR on intestinal biopsies</td>
<td>Mycobacteria detected in approx. 50% of samples from all groups</td>
</tr>
<tr>
<td>Ref. 244</td>
<td>38</td>
<td>0/27</td>
<td>0/11</td>
<td>PCR</td>
<td>Numbers refer to colon specimens</td>
</tr>
<tr>
<td>Ref. 245</td>
<td>37</td>
<td>0/10</td>
<td>0/27</td>
<td>Multiplex PCR</td>
<td>Biopsy from terminal ileum</td>
</tr>
<tr>
<td>Ref. 246</td>
<td>59</td>
<td>0/21</td>
<td>0/14 UC 0/24 controls</td>
<td>PCR</td>
<td>Faeces, sera and intestinal tissue samples</td>
</tr>
<tr>
<td>Ref. 247</td>
<td>37</td>
<td>1/21</td>
<td>0/5 UC 0/11 controls</td>
<td>PCR Culture</td>
<td>Intestinal mucosal biopsies and surgical resections. One PCR positive was obtained. All cultures were negative.</td>
</tr>
<tr>
<td>Ref. 248</td>
<td>51 specimens</td>
<td>0/34</td>
<td>0/17</td>
<td>PCR IS900</td>
<td>biopsies and surgical resections including lymph nodes was used</td>
</tr>
<tr>
<td>Ref. 249</td>
<td>94</td>
<td>0/47</td>
<td>0/27 0/20</td>
<td>PCR various primers</td>
<td></td>
</tr>
<tr>
<td>Ref. 250</td>
<td>40</td>
<td>0/13</td>
<td>0/14 UC 0/13 controls</td>
<td>PCR</td>
<td>Samples of intestine</td>
</tr>
</tbody>
</table>
7.2 Immunological responses to Map in humans with Crohn's disease.

*Map* is very closely related to other MAC and organisms of the *M.intracellulare* complex. Analysis of the 5' region of 16S DNA used for taxonomy shows complete sequence identity between *Map* and *M.intracellulare* serovars 4, 5, 6, 8, 9, 10 and 11 and only a single base pair difference from other *M.avium* sp.262. MAC are widely distributed in the environment and can be isolated by faecal culture from healthy persons263,264. Immunological recognition of MAC antigens is therefore widespread in the general population265,266.

A serological study in 1980 attempted to identify agglutination of three strains of *Map* by Crohn's disease sera. No response was seen with two of the strains, and the agglutination observed with the third *Map* strain showed no difference between Crohn's disease and normal sera267. Between 1984 and 1994 five research groups in the USA, Italy, UK and Argentina used crude extracts of "*M.paratuberculosis* strain 18" in ELISAs to look for differences in antibody binding between Crohn's disease and control sera268,269,270,271,272. With one exception268, no differences were reported. In the context of human infection specifically with *Map*, these studies are of doubtful validity because "*M.paratuberculosis* strain 18" is not *Map* at all, but an *M.avium* sp.273. Despite this, three out of the four negative studies were interpreted as providing evidence against a causal relationship between *Map* and Crohn's disease. Three further studies in 1988-1993 used crude extracts of human *Map* strain Linda or a *Map* of animal origin coated on ELISA plates, to look for differences in antibody binding between Crohn's disease and control sera. No differences were found274,275,276. A recent study from Japan277 however, reported a significant increase in IgG binding to a crude protoplasmic extract of *Map* by Crohn's disease sera compared with normal controls (p<0.05). Three other research groups have tested for differences in peripheral blood or mucosal cell-mediated immune (CMI) responses to sonicates of *Map*, heat killed *Map*, or PPD preparations of *Map* between Crohn's disease and control subjects; again no differences were found278,279,280. The authors of all these negative serological and CMI studies concluded that their data do not support a mycobacterial aetiology for Crohn's disease.

On the other hand, animal health care workers who may be repeatedly exposed to high dose bacillary-form *Map* develop immunological responses to these organisms. These responses can be detected using crude antigen extracts of *in vitro* cultured bacillary-form *Map* and are significantly different from those of control subjects who do not have such a high level of exposure281. However the crude antigens used would also detect immune responses to many other members of the MAC complex to which these workers were likely to be exposed so these results cannot be regarded as specific for *Map*.

These studies and the various interpretations that have been placed on them suffer from the inherent difficulty that a considerable proportion of the population has been exposed and has immunity to MAC to which *Map* belongs and is very closely related. We might not expect to detect differences in serological or CMI reactivity between
people with Crohn's disease and other people with the crude antigenic preparations used.

More recent work (see Table 10) has focussed on antibody recognition of selected proteins and peptides of *Map*. Eighty four percent of Crohn's disease sera were found to recognise one or more of three proteins of 38-kDa, 24-kDa, and 18-kDa from *Map*\(^{282}\), though these are known to have homologues in other mycobacteria. Research has demonstrated significant recognition by one third of Crohn's disease sera, of a specific B-cell epitope in the carboxyterminal 13.6-kDa portion of the 34-kDa component of the A36 immunodominant complex of *Map*. This target is also recognised by sera from cattle infected with *Map*\(^{173, 175}\). El-Zaatari *et al* identified *Map* proteins p35 (the rediscovered above cited 34-kDa protein) and p36 by screening a genomic expression library of *Map* with rabbit antisera\(^{283, 284}\). In one study the p36 antigen was recognised by 86% of Crohn’s disease sera and by 11% of patients with UC, non IBD and also healthy (non BCG vaccinated) subjects. However 100% of BCG vaccinated subjects also reacted as did 89% of patients with tuberculosis or leprosy\(^{285}\). In a further study using both the p35 and p36 antigens, 74% of sera from patients with Crohn’s disease reacted to both antigens whereas no healthy controls and only 1 out of 10 UC patients sera also reacted to both antigens\(^{286}\).
Table 10. Immunological responses in patients with Crohn’s disease

<table>
<thead>
<tr>
<th>Study Ref.</th>
<th>Antigen used</th>
<th>Total Subjects</th>
<th>Positive results in CD patients</th>
<th>Results in controls</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ref. 282</td>
<td>38kD</td>
<td>67</td>
<td>16/28</td>
<td>20 UC 18 healthy controls (all BCG vaccinated) 84% of CD patients positive to at least 1 of the 3 antigens 18% positive to all three No correlation between responses to the three antigens</td>
<td></td>
</tr>
<tr>
<td>24kD</td>
<td></td>
<td></td>
<td></td>
<td>0/20 UC</td>
<td></td>
</tr>
<tr>
<td>18kD</td>
<td></td>
<td></td>
<td></td>
<td>2/20 UC</td>
<td></td>
</tr>
<tr>
<td>173 175</td>
<td>Polypeptide A362</td>
<td>122</td>
<td>73</td>
<td>50</td>
<td>36% of patients with CD had anti-A362 IgA titres significantly higher than the control group. Distribution in CD group was bimodal</td>
</tr>
<tr>
<td>Ref. 285</td>
<td>p36</td>
<td>199</td>
<td>77/89</td>
<td>16/18 with TB or Leprosy 5/42 UC and non IBD 10/10 BCG vaccinated controls 4/40 non BCG vaccinated controls</td>
<td></td>
</tr>
<tr>
<td>Ref. 286</td>
<td>p36</td>
<td>98</td>
<td>40/53</td>
<td>1/10 UC 3/35 H</td>
<td></td>
</tr>
<tr>
<td>p35</td>
<td></td>
<td>166</td>
<td>79/89</td>
<td>4/27 UC 5/50 H</td>
<td></td>
</tr>
<tr>
<td>p35+p36</td>
<td></td>
<td>98</td>
<td>39/53</td>
<td>1/10 UC 0/35 H</td>
<td></td>
</tr>
<tr>
<td>Ref. 289</td>
<td>Serum IgA binding to mycobact-erial HupB protein</td>
<td>30</td>
<td>9/10</td>
<td>0/10 UC 0/10 healthy Cut off was mean+2sd of healthy control group</td>
<td></td>
</tr>
</tbody>
</table>

UC=Ulcerative Colitis H= Healthy control IBD Inflammatory Bowel disease

A peptide epitope in the carboxyterminal 12-kDa portion of p43 encoded by IS900 has been identified which is recognised by IgG from Crohn's disease sera but also sera from each of the other control groups. Recent work has shown that anti-neutrophil cytoplasmic antibodies (pANCA) are a marker for the immune response in inflammatory bowel disease patients, including a subset of Crohn's disease patients. Histone H1 and the *M. tuberculosis* histone-like protein HupB were identified as a pANCA autoantigen and as a pANCA cross-reacting antigen, respectively.
Homologues of the *M. tuberculosis* HupB protein were also found to react with pANCA Igs in several other mycobacterial species, including *Map*. It was also shown that the sera of 9 out of 10 patients with Crohn's disease contained IgA directed against the *M. tuberculosis* HupB protein (p<0.001).

The results of these studies indicate a relatively weak recognition of *Map* in Crohn's disease which is only visible if certain immunological targets are selected. The specificity of antibodies to *Map* is not completely known and the possibility of cross reactions with other members of the MAC must be borne in mind. In addition, people suffering from Crohn's disease have a 'leaky' intestine and readily form antibodies to intestinal bacteria\(^{290}\) and components of food such as *Saccharomyces cerevisiae*\(^{290, 291, 292, 293}\). The design of many, if not all, of the above cited studies fails to adequately take account of this factor and the effect it might have on the immune response of patients with Crohn's disease. Thus weak immunological reactivity to specific *Map* components in Crohn's disease could be secondary to 'bystander' mycobacteria colonising the intestine as a result of Crohn's disease induced mucosal disruption, or an expression of the ability of *Map* to evade immune recognition, a strategy widely used by other pathogens\(^{294}\).

### 7.3 Treatment of Crohn's disease with antimycobacterial drugs.

If *Map* is involved in the causation of Crohn's disease, it may be that drugs active against *Map* would produce clinical improvement in affected patients and in this sense the results of treatment may provide clues to the causation of the disease. However the results of such trials should be treated with caution for two reasons. Firstly, there is no guarantee that even if the disease were caused by mycobacteria that it would respond to treatment and secondly a clinical response could be caused by a non specific antibacterial or antimycobacterial response and may not be related specifically to *M. avium* subsp. *paratuberculosis*. It must also be considered that human drug trials have, in many cases, been conducted on the most resistant cases of the disease i.e. on patients which have failed to respond to more conventional therapy. This section examines the various attempts to treat Crohn's disease with antimycobacterial drugs.

From 1975 to 1989 there were 11 anecdotal reports and open studies of the use of antimycobacterial drugs in the treatment of Crohn's disease. In 1975 Ward and McManus reported a marked clinical improvement in 4 of 6 patients with Crohn's disease treated with dapsone\(^{295}\). A more extensive study in 1977 reported that 40 of 52 patients with severe Crohn's disease treated with various combinations of rifampicin, isoniazid, streptomycin and ethambutol, showed clinical improvement, though the disease itself could not be fully cured \(^{296}\). A similar improvement was reported in Crohn's disease patients treated with rifampicin\(^{297}\). Schultz *et al.* described the complete remission of severe Crohn's disease in a 52 year old man treated with rifampin, isoniazid, pyrazinamide and ethambutol\(^{298}\). The same drug combination used in a 60 year old man with co-existing pulmonary tuberculosis and severe Crohn's disease, was followed by the cessation of diarrhoea of up to 6 times a day for the first time for 16 years, and weight gain from 43 to 51.5kgs\(^{299}\). Further examples of Crohn's
disease responding to anti-tuberculous drugs were also reported by various researchers\textsuperscript{300,301,302,303,304}. Taken together, these case reports and open studies represent the cumulative experience of this treatment approach in a total of 107 selected Crohn's disease patients from 11 different centres throughout North America and Western Europe.

The message, which is consistent, is that there is a very small sub-group of people with Crohn's disease who do show clinical improvement which is occasionally dramatic, in response to treatment with conventional anti-tuberculous chemotherapy. With few exceptions however, clinical improvement is not lasting and complete cure has not been achieved.

A significant beneficial effect of antimycobacterial drugs to a larger proportion of people with Crohn's disease has not been substantiated in most randomised controlled trials. Shaffer \textit{et al.}\textsuperscript{305} found no subsequent difference in Crohn's disease activity index between 14 patients treated with rifampicin and ethambutol and 13 placebo control patients. A study in 28 patients found that clofazimine used as a single agent was ineffective in inducing remission in Crohn's disease\textsuperscript{306}. Rutgeerts \textit{et al}, reported that rifabutin and ethambutol did not prevent recurrent Crohn's disease in the neoterminal ileum after surgery for Crohn's disease\textsuperscript{307}. In a further study\textsuperscript{308}, Prantera \textit{et al.} randomised 40 patients with severe refractory steroid-dependent Crohn's disease to receive rifampicin, ethambutol, clofazimine and dapsone, or placebo. Significant improvement in biochemical and haematological parameters in the treatment group compared with controls occurred, together with a relief of symptoms. In a controlled trial of rifampicin, isoniazid and ethambutol versus placebo, Swift \textit{et al.}\textsuperscript{309} reported a significant reduction in abdominal pain, improvement in well-being score and reduction of abdominal mass at 2 months in the treated, compared with the control group. This apparent improvement was not however maintained, and no long term advantage in the course of the disease was subsequently seen\textsuperscript{310}. These controlled trials involved a cumulative total of 245 patients.

Comparison of the results of treating \textit{Map} infections in animals, and Crohn's disease in humans with antimycobacterial drugs need to be approached with care. Naturally occurring and experimental \textit{Map} infection in animals almost always represents pluribacillary disease with the organisms having established mycobacterial cell walls. It has been theorised that the situation in Crohn's disease would be one in which \textit{Map} would be present in very low abundance (see section 7.1), and with the organisms in a non-bacillary phenotype, so that differences in drug susceptibility between the animal and human disease, might occur. Despite this there are obvious similarities in the outcome of the treatment of \textit{Map} infected animals and of humans with Crohn's disease using antimycobacterial drugs. The impression in both cases is that, whereas on some occasions clinicopathological improvement may follow the use of combinations of multiple agents, remission is unlikely to be sustained and a complete cure will not be achieved. This is consistent with what has long been known, that MAC in general are resistant to standard anti-tuberculous drugs\textsuperscript{311,312,313}. MAC can prevent these agents from penetrating the mycobacterial cell and can rapidly develop mutations which confer drug resistance\textsuperscript{314,315,316,317,318}. MAC infections in immunocompetent hosts are difficult to eradicate; prolonged treatment is required and relapse either on treatment or off treatment is common.
An advance in the treatment of MAC infections in both HIV and non-HIV patients, as well as in the availability of candidate drugs for the treatment of Crohn's disease, came with the development of a new series of therapeutic agents which are chemical modifications of natural streptomycetes antibiotics. Of particular relevance was rifabutin (ansamycin), a derivative of rifamycin-S$^{319,320}$, the macrolide clarithromycin, a derivative of natural erythromycins and the azalide azithromycin. These agents were found to have markedly improved activity against MAC in vitro$^{321,322,323,324,325}$ both alone and in combination with other agents. They also have the particular advantage of being concentrated within macrophages and other cells$^{326}$. Furthermore rifabutin and clarithromycin demonstrated good activity in vitro against Map$^{327,328}$ and appear to synergise$^{329}$. Early studies of the use of rifabutin in primates (macaques) naturally infected with Map$^{330}$, and in 6 patients with Crohn's disease, were promising$^{331}$. A preliminary report of a controlled trial of monotherapy with clarithromycin in 15 Crohn's disease patients, demonstrated sustained remission in the treatment group$^{332}$; however a subsequent study of clarithromycin and ethambutol failed to show any benefit in Crohn's disease$^{333}$. Monotherapy with clarithromycin may be followed by an initial 'honeymoon' response in active Crohn's disease, but it invites the development of drug resistance and should be avoided$^{334,335,336,337,338}$. Both rifabutin and clarithromycin target microbial protein synthesis rather than inhibition of cell wall biosynthesis and were predicted to be applicable to the non-bacillary phenotype of Map in Crohn's disease. A two year outcomes analysis of the use of rifabutin together with clarithromycin or azithromycin in the treatment of 46 patients with active Crohn's disease was initiated in 1992. This study$^{339}$ demonstrated a highly significant improvement in the disease activity index in patients after 6 months treatment which was maintained at 2 years (p<0.001), and a significant improvement in inflammatory parameters. The efficacy of rifabutin and macrolide therapy in active Crohn's disease was further supported by work carried out independently in Australia$^{340}$. A randomised double blind controlled multicenter trial of a combination of rifabutin, clarithromycin and clofazimine versus placebo on a background of standard prednisone immune suppression, was initiated in Australia in September 1999. The results of this study are not expected to be available before the middle of 2002.
8. Exposure of human populations to *M. avium* ssp. *paratuberculosis*

This chapter examines whether it is possible for the human population to be exposed to *Map* and therefore whether the opportunity exists for humans to become infected with the organism. In theory, humans could come in contact with *Map* by direct contact with other humans or animals or by indirect means such as diet.

### 8.1 Non-dietary exposure

Faeces of animals with the multibacillary form of paratuberculosis contain enormous numbers of *Map*. Humans coming in contact with either clinically or subclinically infected animals are therefore liable to be exposed to large numbers of the bacteria. Occupational groups affected would include farmers, veterinarians and abattoir workers. However a conspicuously high incidence of Crohn’s disease has not been reported in these occupational groups though large scale epidemiological studies are required.

The possibility of spread from humans has been mentioned earlier in Chapter 7, though the main possibility could be from faecal contamination. However, while *Map* has been cultured from the faeces of Crohn’s disease patients and healthy people, the number of organisms involved appears to be very small. However, the recent report of the detection of *Map* in breast milk of mothers with Crohn’s disease could provide a means by new generations could be exposed to *Map*. This finding is based on only two cases so more work is required to determine the extent of the issue. On the other hand, previous epidemiological work has indicated that patients with Crohn’s disease were over represented among those who had received little or no breast feeding. Higher levels of Crohn's disease have not been reported in the spouses of patients with Crohn’s disease.

### 8.2 Dietary exposure.

#### 8.2.1 Raw milk

It has long been known that *Map* can be cultured from raw milk of clinically infected cows with paratuberculosis. It is probable that the organisms are present within the monocyte population abundant in milk, but they also occur extracellularly. More recent work has shown that *Map* can also be cultured from the milk of apparently healthy subclinically infected cows. Sweeney et al., cultured *Map* from the milk of 19% of healthy cows which were heavy faecal shedders of *Map*, and from the milk of 5% of healthy cows which were intermediate or light shedders of the organism. Streeter et al cultured *Map* from the colostrum and milk of 30% of faecal culture positive clinically normal animals. Relying as they do on the ability of the *Map* from these animals to survive decontamination by overnight incubation in 0.75%
hexadecylpyridinium chloride (HPC) and then be culturable, such studies inevitably underestimate the true prevalence of these difficult-to-culture organisms.

Given the high prevalence of Map in the dairy herds and domestic livestock of western Europe and North America, it is inevitable that Map will from time to time be present in bulked tank milk being brought to pasteurisation plants. This raw milk is normally subjected to treatment either by pasteurisation, UHT treatment or sterilisation. The proportion of milk consumed in each of these categories varies considerably throughout Europe.

8.2.2 Heat treated milk

Because of the difficulty in culturing the organism, it has proved problematic to experimentally determine the efficiency of treatments such as pasteurisation. Since 1993 seven studies have shown that Map prepared in in vitro cultures, spiked into whole cows' milk at a range of microbial concentrations and then treated with experimental pasteurisation, remained culturable from some samples, after exposure to 65°C for 30 minutes (the Standard Holder method) or 72°C for 15 seconds (the High Temperature Short Time method). These studies have been criticised principally on the grounds that experimental pasteurisation does not accurately reproduce the conditions such as turbulent flow which occur in commercial pasteurisation units. In addition, because of the presence of the organism in monocytes, spiking studies may not be representative. Two other studies reported the complete loss of culturability of Map spiked into milk and heated to 72°C for 15 seconds in either a laboratory scale pasteuriser unit, or in capillary tubes submerged in a circulating water bath though the procedures used have also been criticised.

An extensive survey carried out in England and Wales in 1990-1994 found that an overall 7% of cartons and bottles of retail whole pasteurised cows' milk tested positive for Map by IS900 PCR. The test detection limit was estimated to be about 200 Map ml\(^{-1}\). Liquid cultures inoculated with Map-positive samples of cream or pellet, subsequently demonstrated the microscopic presence of sparse clumps of acid fast organisms when examined in the time frame 4 to 12 weeks of incubation. These cultures in multiple flasks were themselves strongly positive by IS900 PCR and suggested the presence of residual Map. These cultures invariably went on to become overgrown by other organisms, and proof of live Map by subculture onto solid media was not obtained.

Subsequent research using raw milk spiked at 10\(^6\) cfu ml\(^{-1}\), has confirmed the ability of these organisms to survive pasteurisation conditions at 72°C for 15 seconds, as well as demonstrating a considerable range in the heat tolerance of different strains of Map right up to residual culturability after 90°C for 15 seconds. However, none of the strains investigated remained culturable after exposure to 72°C for 25 seconds, suggesting that extension of the holding time is more likely to achieve complete inactivation of Map in milk. Ongoing work in the same laboratory, using improved sample processing procedures such as immunomagnetic capture of Map and optimised decontamination prior to culture and IS900 PCR, is currently demonstrating...
Map in a small percentage of samples of retail pasteurised cows' milk. A recent interim report of ongoing work in the UK has reported the finding of viable Map in around 5% of raw milk samples examined and in about 3% of pasteurised samples examined 362, although no information is yet available on the numbers of organisms present.

8.2.3 Other foods

Because of its presence in raw milk, Map may be initially present in cheeses made from raw milk from infected animals, or in those made from milk exposed to pasteurisation at lower temperature prior to the cheese-making process. MAC are generally resistant to acid conditions and are known to be able to resist the acidic conditions created in intracellular phagolysosomes as part of their strategy for survival within the host cell. MAC may thus survive low pH conditions involved in cheese-making, although the recovery of MAC from cheese, by growth in conventional culture, may be unreliable. At the present time there are no publications from laboratory based research specifically addressing the question of whether Map is present in cheese, but epidemiological studies for environmental risk factors for MAC in patients with HIV disease, identified an increased risk associated with the consumption of hard cheeses 363.

Macrophages containing Map are known to be found throughout the body of animals with the advanced pluribacillary form of Johne's disease. Most tissues including lymph nodes, spleen, bone marrow, liver, kidney and lung are affected but titres of bacteria are low.

8.2.4 Water supplies.

Other M. avium complex (MAC) organisms, widely distributed in the environment and in natural waters, act as a source of nontuberculous mycobacterial disease in humans where infection is acquired by environmental exposure 364, 365, 366. Drinking water is known to act as a source of M. avium superinfections in humans with AIDS and primates with SIV 367, 368. Both subclinically and clinically infected livestock shed abundant quantities of Map onto pastures. Unlike M. bovis, Map can survive in the environment for prolonged periods 369, 370, 371. An unquantified further contribution to the environmental contamination by Map will be made by wildlife hosts such as infected deer, rabbits, foxes, stoats, and weasels 362, 372.

The possibility of Map entering lakes or rivers where considerable dilution would take place will depend on local topography and soil types. There is a general need to increase the volume and intensity of environmental research into Map within Europe.
9. Summary

This report has confined itself to an examination of the possibility that Crohn’s disease is caused by *Mycobacterium avium* subsp. *paratuberculosis*. It has not examined other possible causes of the disease in detail.

1. *Mycobacterium avium* subsp. *paratuberculosis* (*Map*) is an organism which can cause chronic inflammation of the intestine (Johne's disease) in cattle, sheep and goats as well as in other animals including rabbits and macaques.

2. *Map* infections are widespread in domestic livestock, including cattle, sheep and goats. Rabbits, deer and other animals have been identified as wildlife hosts of *Map*.

3. Animals can harbour *Map* without showing signs of disease or reacting to serological tests.

4. *Map* is found in large quantities in the intestine of diseased animals and in lesser amounts in lymph nodes, liver, spleen and other tissues.

5. Clinically infected animals may shed up to $10^{12}$ *Map* per ml in their faeces. Subclinically infected animals also shed the organism though usually in lower amounts. Infected dairy cows and sheep shed *Map* in their milk.

6. *Map* can survive for prolonged periods (up to 9 months) on contaminated pastures and in the environment.

7. *Map* infections in animals are usually acquired at an early age from faeces contaminated environments and from milk, younger animals being more susceptible than adults.

8. Paratuberculosis in animals presents a range of histopathological types from multibacillary to lymphocytic/paucimicrobial forms.

9. *Map* is a very slow growing organism. Laboratory culture is a time consuming and insensitive means of detecting low levels of contamination by *Map* in environmental and food samples. In animals, faecal culture is regarded as the gold standard for diagnosis but it is slow and dependent on the organism being present in the faeces.

10. Immunological assays for *Map* infection in animals generally have poor sensitivity or poor specificity and can be unreliable, particularly for the early detection of infection.

11. Genetic analyses have revealed different strains of *Map*. 

52
12. *Map* contains 14-18 copies of a specific DNA insertion element (IS900) which can be used to detect the presence of *Map* DNA. These PCR tests can be very sensitive when optimal sample processing procedures and reaction conditions are used.

13. *Map* is more robust than *M. tuberculosis* and *M. bovis*. The complete destruction of all viable *Map* in milk by pasteurisation at 65°C for 30 minutes or 72°C for 15 seconds, may not be assured. Viable *Map* has been identified in pasteurised milk supplies.

14. There is preliminary evidence that *Map* may be present in human milk. If these initial results are confirmed, this would be a significant finding.

15. Crohn's disease is a chronic inflammation of the intestine in humans which presents some clinical and pathological similarities to the lymphocytic/paucimicrobial form of paratuberculosis in animals.

16. Crohn's disease occurs in Western European countries with an overall incidence of 5.6 per 100,000 individuals per year.

17. Insufficient data are available to compare the incidence and prevalence of Crohn’s disease and paratuberculosis so as to determine epidemiological links between both diseases.

18. *Map* has been detected in approximately 30% of pathological samples from patients with Crohn's disease by IS900 PCR tests and also, at a lower level, in healthy people. *Map* can only be grown in conventional culture in about 5% of cases and then only after months or years of incubation.

19. The results of IS900 PCR tests on DNA extracts of Crohn's disease intestine carried out in many different laboratories have been conflicting. Several studies which succeeded in detecting *Map* in patients with Crohn’s disease also detected the organism in a smaller percentage of healthy subjects. Other studies were unable to detect the organism.

20. Crohn's disease patients display an increased serological response to many intestinal micro-organisms including *Map*. This may simply reflect an increased immunological response in patients to many micro-organisms perhaps as a consequence of a 'leaky intestine'.

21. A few Crohn's disease patients show clinical remission when treated with anti-tuberculosis drugs, but relapse usually occurs. New drugs such as rifabutin and macrolide antibiotics active against *M. avium* sp., are reported to be effective in higher numbers of Crohn's disease patients in open studies, though relapse still occurs. Results of large-scale well designed controlled therapeutic trials are not yet available.
10. Research

10.1 Crohn’s disease

Further research is required to resolve this important issue raised in the request from the Commission. This research should be targeted on the following aspects;

1. Large scale epidemiological studies of Crohn’s disease patients to examine risk factors, particularly in early life.

2. Attempts to localise the presence and pathology of *M avium* subsp. *paratuberculosis* in the human gut. The significance of the finding of spheroplasts in this disease needs to be determined.

3. Follow up work to fully evaluate recent findings such as the finding of *M avium* subsp. *paratuberculosis* in breast milk and immunological recognition of mycobacterial and *Map* components in man.

4. Large scale multi-centre double blind drug trials using combination therapy of those drugs liable to be active against *Map*, preferably on patients in whom *M paratuberculosis* has been detected.

5. Experiments should be carried out both *in vitro* and *in vivo* to determine possible methods of transmission.

Facilitating the creation and maintenance of a network of researchers at EU level combining expertise in chronic inflammatory bowel diseases in humans and in *mycobacterium* sp. infections in animals, would greatly contribute to attaining these goals.

10.2 Paratuberculosis

Aside from any possible link with Crohn’s disease, the development of the necessary tools to eradicate paratuberculosis from animals should also be a priority.

1. Improvement diagnostic methods are required and their development should be encouraged. There is a need to validate the methodology of currently used diagnostic methods, particularly sample preparation methods. Comparative testing between various laboratories should be carried out.

2. The development of efficient vaccines and diagnostic tests to distinguish infected and vaccinated animals.

3. All these activities would be greatly accelerated by the availability of the complete genomic sequence of *Map*. 
4. The distribution and levels of *Map* in infected animals should be determined.

5. Experiments with various time temperature combinations for pasteurisation should be carried out to determine optimum combinations to inactivate the *Map* bacterium.

6. The survival of *Map* in the environment and the role of natural water and water supplies in the transmission of paratuberculosis needs to be determined.

7. Statistically robust studies on the prevalence of Map in domestic and wild animals should be carried out. These will be of assistance for future eradication programmes and will also allow comparisons to be carried out with the geographical prevalence of Crohns disease.
11. Conclusions

The currently available evidence is insufficient to confirm or disprove that *Mycobacterium paratuberculosis* is a causative agent of at least some cases of Crohn’s disease in man.

There are sufficient grounds for concern to warrant increased and urgent research activity to resolve the issue. This research is described in section 10.1 of this report.

Crohn’s Disease is most likely a multifactorial condition. Its incidence is more common in the western world, in families where there have been other cases and in homes where hygiene in early life has been good. There are considerable clinical and pathological similarities, though also some significant differences between paratuberculosis in animals and Crohn’s Disease in man.

The organism *Mycobacterium avium* subsp *paratuberculosis* (*Map*) is relatively common and it is likely that many people have come into contact with it. The detection of *Map* in a greater proportion of Crohn’s disease patients than in controls suggests that the organism may have a role either as a causative agent, as a secondary invader which exacerbates the disease or as a non pathogenic coloniser because of changed bowel conditions.

Exposure to high levels of the organism can arise from direct contact with infected farm animals or by drinking raw milk from infected animals. Exposure to lower levels of the organism could possibly arise from heat treated milk or from sources such as wildlife hosts. A simple relationship between exposure to high (or low) levels of organisms and the development of Crohn’s disease does not appear to exist.

If *Map* is involved in the causation of Crohn’s disease, it would also require the presence of other susceptibility factors. It is also possible that its involvement may relate to a sub set of Crohn’s disease cases.

The current tools available to control paratuberculosis in animals are inadequate. Using current methods, eradication programmes are likely to be long lasting, expensive and with low probability of success, particularly in endemic areas. Because paratuberculosis is an economically significant disease, the development of tools, such as efficient diagnostic tests, to enable eradication would be extremely beneficial and would encourage eradication programmes throughout the world.

Results from recent drug trials in humans with drugs likely to be active against *Map* have been encouraging but inconclusive. Larger scale double blind studies are in progress to obtain better data.
12. References


44 Pavlik I; Horvathova A; Dvorska L; Bartl J; Svastova P; du Maine R; Rychlik I. (1999). Standardisation of restriction length polymorphism analysis for Mycobacterium avium subspecies paratuberculosis. J. Microbiol Meth. 38, 155-167

45 Whittington R; Marsh I; Choy E; Cousins D (1998) Polymorphisms in IS1311, an insertion sequence common to Mycobacterium avium and M. avium subsp. paratuberculosis, can be used to distinguish between and within these species. Mol. Cell. Probes, 12, 349-358


47 Arbeit, R.D.; Slutsky, A.; Barber, T.W.; Maslow JN; Niemczyk S; Falkinham JO; O'Connor GT; von Reyn CF. (1993). Genetic diversity among strains of Mycobacterium avium causing monoclonal and polyclonal bacteremia in patients with AIDS. J. Infect. Dis. 167, 1384-1390


52 Feizabadi MM; Robertson ID; Hope A; Cousins DV; Hampson DJ (1997) Differentiation of Australian isolates of Mycobacterium paratuberculosis using pulsed-field gel electrophoresis. Aust Vet J.; 75(12):887-9

53 Hughes, personal communication

54 Bull, T.; Pavlik, I.; Hermon-Taylor, J.H.T.; El Zaatari, F.; and Tizard M.; Study of IS900 loci in Mycobacterium avium subsp. paratuberculosis by multiplex PCR screening In Proceedings of the Sixth International Colloquium on Paratuberculosis, Melbourne , Australia; Eds. Manning E.J.B. and Collins M.T.


Beard PM; Henderson D; Daniels M; Pirie A; Buxton D; Greig A; Hutchings MR; McKendrick I; Rhind S; Stevenson K; Sharp M. (1999) Evidence for paratuberculosis in fox (vulpes vulpes) and stoat (mustela erminea). Vet. Rec., 145, 612-613


Jones DG; Kay JM. (1996), Serum biochemistry and the diagnosis of Johne's disease (paratuberculosis) in sheep. Vet Rec,139, 498-499
85 Shivananda S; van Blankenstein M; Schouten WR et al. (1993) Quality of life in Crohn’s disease: results of a case-control study. Euro J Gastroenterol &Hepatol; 5: 919-925
86 Gent AE; Hellier MD; Grace RH; Swarbrick ET; Coggon D. (1994) Inflammatory bowel disease and domestic hygiene in infancy. Lancet; 343: 766-767
89 Crohn BB; Ginzburg I; Oppenheimer GD. (1932) Regional ileitis: a pathologic and clinical entity. JAMA, 99:1323-1328
90 Dalziel TK. Chronic intestinal enteritis. B. M. J. 1913;2:1068-1070
91 Lockhart-Mummery HE; Morson BC. (1960) Crohn’s disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut; 1:87-105
94 World Health Organisation concludes that measles viruses are not associated with Crohn's disease. Commun Dis Rep CDR Wkly 1998 Feb27;8(9):75,78
97 Cosnes J; Carbonnel F; Beugerie L; Le Quintrec Y; Gendre JP. (1996) Effect of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology; 110: 424-431
98 Sutherland JR; Ramcharan S; Bryant H; Fick G. (1990). Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology; 98: 1123-1128
101 Bayless TM; Tokayer AZ; Polito JM 2nd; Quaskey SA; Mellits ED; Harris ML. (1996) Crohn’s disease: concordance for site and clinical type in affected family members -potential heredity influences. Gastroenterology, 111:573-579
102 Polito JM; Rees RC; Childs B; Mendeloff AI; Harris ML; Bayless TM. (1996) Preliminary evidence for genetic anticipation in Crohn’s disease. Lancet, 347:798-800
104 Satsangi J; Jewell DP; Rosenberg WMC, Bell JI. (1994) Genetics of Inflammatory Bowel Disease: A progress report. Gut; 35: 696-700
106 Hugot JP, Laurent-Puig P; Gower-Rousseau C; Olson JM; Lee JC; Beaugerie L; Naon I; Dupas JL; Van Gossuin A, Orholm M; Bonaiti-Pellie C; Weissenbach J; Mathew CG; Lennard-Jones JE; Cortot A; Colombel JF; Thomas G. (1996) Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature, 379:821-823
107 Reinshagen M; Loelinger C; Kuehnl P; Weiss U; Manfras BJ; Adler G; Boehm BO. (1996) HLA class II genes with susceptibility to Crohn’s disease. Gut 1996, 38:538-542
108 Satsangi J; Welsh KI; Bunce M; Julien C; Farrant JM; Bell JI; Jewell DP. (1996) Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996, 347:1212-1217
Danze PM; Colombel JF; Jacquot S; Loste MN; Heresbach D; Ategbo S; Khamassi S; Perichon B; Semana G; Charron D; Cezard JP. (1996) Association of HLA class II genes with susceptibility to Crohn’s disease. Gut, 39:69-72

Parkes M; Satsangi J; Dewell DP. (1997) Inflammatory bowel disease genetics: narrowing the region of linkage on chromosome 12. Gut, 41 (suppl 3) A35


Berrebi D; Besnard M; Fromont-Hankard G; Paris R; Mougenot JF; DeLAGausie P; Emilie D; Cezard JP; Navarro J; Peuchmair M. (1998) Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am J Pathol;152(3):667-72


Louis E; Belaiche J; van Kemseke C; Franchimont D; de Groote D; Gueenen V; Mary JY. (1997) A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur. J. Gastroenterol. Hepatol.; 9(10):939-44


Herfarth HH; Mohanty SP; Rath HC; Tonkonogy S; Sartor RB. (1996) Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut; 39(96):836-45

Plevy SE; Landers CJ; Prehn J; Carramananza NM; Deem RL; Shealy D; Targan SR (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 15;159(12):6276-82


Hirata I; Berrebi G; Austin LL; Keren DF; Dobbins WO (1986) Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and in inflammatory bowel disease. Dig Dis Sci. 31(6):593-60


137 Boelaert F.; Walravens K.; Vermeersch J.P.; Raskin A.; Dufey J.; J. Godfroid. Sample survey for estimating the herd and individual animal seroprevalence for bovine paratuberculosis in Belgium (submitted. Vet microbiol)


144 Shivananda S; Lennard-Jones JE; Logan RF; Fear N; Price A; Carpenter L; Van Blankenstein M; and the EC-IBD Study Group.(1996) Incidence of Inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). *Gut*, 39:690-697


Gilmour NJL; Angus KW. (1971) Effect of the rimino phenazine B663 (G30320) on Mycobacterium johnei infection and reinfection in sheep. J. Comp. Path.;81:221-226


Hoffsis GF; Streeter RN; Rings DM; St.Jean G. (1990) Therapy for Johne's disease. The Bovine Practitioner; 25:55-58


Moss MT; Sanderson J; Tizard MLV; Hermon-Taylor J. (1992) PCR detection of Mycobacterium paratuberculosis in long term cultures from Crohn's disease tissue. Gut; 33:1209-1213.

Wall S; Kunze ZM; Saboor S; Soufleri J; Seechurn P; Chiodini R; McFadden JJ. (1993) Detection of Mycobacterium paratuberculosis DNA in stool samples of patients with inflammatory bowel disease by IS900-based PCR and colorimetric detection of amplified DNA. J Microbiol Methods; 33:105-114.
247 Clarkson WK; Presti ME; Petersen PF; Zachary PE; Fan WX; Leonard CL; Vernava AM; Longo WE; Kreeger JM. (1998) Role of Mycobacterium paratuberculosis in Crohn’s disease. Dis Colon Rectum.; 41:195-199
249 Cellier C; De Beenhouwer H; Berger A; Penna C; Carbonnel F; Parc R; Cugnenc P-H; Le Quintrec Y; Gendre J-P; Baribier J-P; Portaels F. (1998) Mycobacterium paratuberculosis and Mycobacterium avium subspp silvaticum DNA cannot be detected by PCR in Crohn’s disease tissue. Gastroenterol. Clin Biol.; 22:675-678
254 Challans JA; Stevenson K; Reid HW; Sharp JM (1994) A rapid method for the extraction and detection of Mycobacterium avium subspp paratuberculosis from clinical specimens. Vet. Rec.; 134(4):95-6
256 Naser S et al. Personal communication. 1999
258 Noordhoek GT; Kolk AHJ; Bjune G; Catty D; Dale JW; Fine PEM; Godfrey-Faussett P; Cho S-N; Shinnick T; Svenson SB; Wilson S; van Embden JDA. (1994) Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J. Clin. Microbiol.; 32:277-284
69
286 Naser SA; Hulten K; Shafran I; Graham DY; El-Zaatari FAK. (1999) Specific seroreactivity of Crohn’s disease patients against p35 and p36 antigens of M avium subsp. paratuberculosis. In: Proceedings of the Sixth International Colloquium on Paratuberculosis, Melbourne , Australia; Pages 525-530. Eds. Manning E.J.B. and Collins M.T.
289 Cohavy O; Harth G; Horwitz M; Eggena M; Landers C; Sutton C; Targan SR; Braun J. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect. Immun.; 67: 6510-17.
293 Ruemmele FM; Targan SR; Levy G;Dubinsky M; Braun J; Seidman EG. (1998) Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology; 115:822-829
300 Piccotto A; Gesu GP; Schito GC; Testa R; Varagona G; Celle G. (1988) Antimycobacterial chemotherapy in two cases of inflammatory bowel disease. Lancet 1(8584):536-7.


granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-

326 Gladue RP; Snider ME. (1990) Intracellular accumulation of azithromycin by cultured human

327 Chiodini RJ. (1991) Antimicrobial activity of rifabutin in combination with two and three other
antimicrobial agents against strains of Mycobacterium paratuberculosis. J. Antimicrob. Chemother.;
27:171-176.

328 Rastogi N; Goh KS; Labrousse V. (1992) Activity of clarithromycin compared with those of other
drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and

329 Ghebremiichael S; Svenson SB; Kallenius G; Hoffner SE. (1996) Antimycobacterial synergism of

330 McClure HM; Chiodini RJ; Anderson DC; Swenson RB; Thayer WR; Coutu JA. (1987)
Mycobacterium paratuberculosis infection in a colony of Stumptail Macaques (Macaca arctoides).

331 Thayer W; Coutu J; Chiodini R et al. Use of rifabutin and streptomycin in the therapy of Crohn's
disease - preliminary results. In: R.P. MacDermott ed. Inflammatory Bowel Disease: current status

332 Graham DY; Al-Assi MT; Robinson M. (1995) Prolonged remission in Crohn's disease following

333 Goodgame RW; Kimball K; Akram S; Graham DY, Ou, C.-N. (1999) Randomized controlled trial

334 Leiper K; Campbell BJ; Rhodes JM. (1999) Treatment of active Crohn's disease with

335 Mei A; Heifets L; Wallace RJ; Zhang Y; Brown BA; Sander P; Bottger EC. (1996) Molecular
mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S

336 Ji B; Lounis N; Truffot-Pernot C; Grosset J (1992) Selection of resistant mutants of
Mycobacterium avium in Beige mice by clarithromycin monotherapy. Antimicrob. Agents and
Chemother.; 36: 2839-2840.

Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment

338 Bermudez LE; Petrofsky M; Kolonoski P; Young LS. (1998) Emergence of Mycobacterium avium
populations resistant to macrolides during experimental chemotherapy. Antimicrob. Agents
Chemother.; 42:180-183

339 Gui GPH; Thomas PRS; Tizard MLV; Lake J; Sanderson JD; Hermon-Taylor J. (1997) Two-year-
Chemother.; 39: 393-400.

340 Borody TJ; Pearce L; Bampton PA et al. (1998) Treatment of severe Crohn's disease (CD) using
rifabutin-macrolide-clofazimine combination: interim report. Gastroenterology; 114: A938

Chron's disease. Scand. J Gastroenterol; 18 903-906

J.; 110: 218.

Bacteriol; 80: 440-442

344 Taylor TK; Wilks CR; McQueen DS. (1981) Isolation of Mycobacterium paratuberculosis from the

345 Sweeney RW; Whitlock RH; Rosenberger AE. (1992) Mycobacterium paratuberculosis cultured
from milk and supramammary lymph nodes of infected asymptomatic cows. J. Clin. Microbiol.; 30:
166-171.

346 Streeter RN; Hoffsis GF; Bech-Nielsen S; Shulaw WP; Rings DM. (1995) Isolation of
Mycobacterium paratuberculosis from colostrum and milk of subclinically infected cows. Am. J.
Rea.; 56: 1322-1324
73


360 Grant IR; Ball HJ; Rowe MT. (1999) Effect of higher pasteurization temperatures, and longer holding times at 72°C, on the inactivation of *Mycobacterium paratuberculosis* in milk. *Letts in Appl. Microbiol.*; 28: 461-465


## 13. Acknowledgements

This report of the Scientific Committee on Animal Health and Animal Welfare is based on the work of a working group established by the Committee. The working group was chaired by Prof. J Badiola. The members of the group are listed below.

**Prof. Juan José BADIOLA**  
Universidad de Zaragoza – Facultad de Veterinaria  
C/. Miguel Servet 177  
E – 50 013 Zaragoza Espana

**Dr. Douwe BAKKER**  
Institute for Animal Science and Health  
P.O.Box 65  
NL – 8200 AB Lelystad Nederland

**Dr. Juan Francisco GARCIA MARIN**  
Facultad de Veterinaria, Universidad de Leon  
Campus de Vagazano  
E – 24071 Leon Espana

**Dr. Philippe GILOT**  
Institut Pasteur, Dépt.de Virologie  
Rue Engeland 642  
B – 1180 Brussels Belgium

**Prof. John HERMON-TAYLOR**  
St George’s Hospital Medical School, Dept. of Surgery  
University of London, Jenner Wing, Cranmer Terrace  
UK – London SW1 7ORE United Kingdom

**Dr. James Michael SHARP**  
Moredun Research Institute, Pentlands Science Park,  
Penicuik EH26 0PZ, Scotland, UK

**Dr. Shiva SHIVANANDA**  
Pres. Kennedylaan 188
Reports of the Scientific Committee on Animal Health and Animal Welfare of the European Union are available at the Committee Website;

http://europa.eu.int/comm/dg24/health/sc/scah/index_en.html

Recent reports include;

<table>
<thead>
<tr>
<th>No.</th>
<th>Title</th>
<th>Date Adopted</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>Possible links between Crohn’s disease and paratuberculosis</td>
<td>21 March 2000</td>
</tr>
<tr>
<td>15</td>
<td>The welfare of Chickens kept for Meat Productiuon (broilers).</td>
<td>21 March 2000</td>
</tr>
<tr>
<td>14</td>
<td>Bacterial Kidney Disease</td>
<td>8 December 1999</td>
</tr>
<tr>
<td>13</td>
<td>Standards for the Microclimate inside animal Transport Road Vehicles</td>
<td>8 December 1999</td>
</tr>
<tr>
<td>12</td>
<td>Estimations of the Infective Period for Bluetongue in cattle</td>
<td>8 December 1999</td>
</tr>
<tr>
<td>11</td>
<td>Diagnostic Tests for Crimean Congo Haemorrhagic Fever in ratites</td>
<td>11 October 1999</td>
</tr>
<tr>
<td></td>
<td>to take account of Scientific Developments regarding Tuberculosis, Brucellosis and Enzootic Bovine Leucosis</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Classical Swine Fever in Wild Boar</td>
<td>10 August 1999</td>
</tr>
<tr>
<td>8</td>
<td>Animal Welfare Aspects of the Use of Bovine Somatotrophin</td>
<td>10 March 1999</td>
</tr>
<tr>
<td></td>
<td>Title</td>
<td>Date</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>7</td>
<td>Strategy for the emergency vaccination against Foot and Mouth Disease</td>
<td>10 March 1999</td>
</tr>
<tr>
<td>6</td>
<td>Welfare Aspects of the production of Foie Gras in Ducks and geese.</td>
<td>16 December 1998</td>
</tr>
</tbody>
</table>